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ABSTRACT
Substance abuse has always been an issue in society. As time has passed, the adverse
consequences of substance abuse have become more evident. These consequences include
physical and mental addiction, disruption of purposeful and productive everyday life, disruption
of the family unit, spread of diseases, and death. Recently, the rate of overdose has rapidly
increased due to the potency and accessibility of illicit opiates. Fentanyl and carfentanyl have
been added to many opioid and non-opioid substances to provide a more euphoric experience, to
intensify the addiction of the client, and for economic reasons because they are much more
potent than heroin. Unfortunately, these products are often deadly, and the number of overdoses
has increased 500 percent over the past ten years in the United States. Individuals with substance
addiction are very likely to have a co-occurring mental illness. In 2017, 7.9 million patients had
diagnosed with co-occurring disorders. Treatments for those with substance use disorders and
co-occurring disorders are under constant scrutiny for their effectiveness. This study investigates
the effectiveness of methadone maintenance treatment comparatively with non-methadone
treatments for those with opioid use disorder and co-occurring disorders. The data was gathered
from an anonymous behavioral health treatment facility that specialized in substance use
disorders in southern Massachusetts. The study analyzed archival data from 1,000 clients’
treatment episodes over 1 year. The clients were randomly chosen, and treatment choices were
identified. The length of time in treatment help to determine whether the treatment is successful
or unsuccessful.

Keywords: methadone, medicated assisted treatments, non-medicated assisted treatments,
opiates, substance use disorder, overdose, recidivism, harm reduction, modality.
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CHAPTER ONE: INTRODUCTION
Overview
Opioids are the most dangerous illicit substances that are abused (Robinson et al., 2019).
More people overdose on opiates than cocaine, amphetamines, stimulants, benzodiazepines,
alcohol, and other categories combined (Bart, 2012). Over half of those who are addicted to
opioids also have a mental health diagnosis (Bureau of Substance Abuse Services [BSAS],
2017). Opioids and opiates include heroin, oxycontin, oxycodone, fentanyl, carfentanyl,
methadone, buprenorphine, morpheme, kratom, tramadol, codeine, hydrocodone, Vicodin,
Percodan, Demerol, Tylox, and Percocet (BSAS, 2017). Many different treatments exist for
those who are addicted to opioids and opiates. The most effective treatments are yet to be
determined. This study attempts to provide insight into the effectiveness of methadone
maintenance as a medicated assisted treatment versus non-medicated assisted treatments for
opioid use disorder and for those with co-occurring opioid use disorder and a mental health
disorder
Background
Opioids are synthetic and semisynthetic pain killers that are chemically derived from
opiates (natural painkillers) to promote their final form (Keary et al., 2012). The only true opiates
are poppy, morpheme, kratom, thebaine, and codeine (Keary et al., 2012). Semisynthetic opioids
are derived from opiates with human intervention to obtain their final form (Kreek et al., 2005).
These include heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and
buprenorphine, among others (Kreek et al., 2005). Synthetic opioids are one hundred percent
chemically manufactured and include methadone, fentanyl, and tramadol (Kreek et al., 2005).
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Opioid addiction is a disease that begins with an individual taking opiates, whether illicit
or prescribed. Either way, it does not take a long time taking opioids before the individual
becomes physically addicted. Many times, opioid use disorder begins with a patient taking a
prescription for an injury, surgery, or illness. They may become addicted and when the
prescription is discontinued by their doctor, they begin to buy it from the street. Prescription pain
killers are much more expensive to buy from the street; therefore, individuals tend to buy a
cheaper opioid, heroin (Mars et al., 2014).
Opioid addiction has caused social issues including crime, homelessness, prostitution,
and violence. It has transformed neighborhoods into dangerous places, torn apart families, and
caused children to grow up without their parents. Many people are incarcerated due to issues
stemming from addiction. Many individuals have medical and physical problems due to
addiction. Moreover, many abusers have died an untimely death (Okie, 2010).
Over half of individuals with opioid use disorder have also been diagnosed with a mental
health disorder (BSAS, 2017). These diagnoses range from mild depression to schizophrenia. It
is difficult to ascertain whether the substance use was a direct result of the mental health
disorder, the mental health disorder is due to the substance use disorder, or individuals who are
biologically or environmentally prone to one are prone to the other. The most common cooccurring mental health disorders are anxiety, depression, borderline personality disorder, and
antisocial personality disorder (Swendsen et al., 2010). For those with a co-occurring disorder, if
the mental health problems are not addressed in sync with the substance use issues, the patient
will have a much higher chance of relapsing (Swendsen et al., 2010).
According to Dr. Schaler, author in the Psychiatric Times, many in the field of substance
abuse treatment refuse to recognize substance use disorder as a disease because it begins
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voluntarily (Schaler, 2002), while others point out that diseases such as lung cancer, obesity, and
certain types of diabetes are also caused by a voluntary act by the patient, but are still socially
accepted as diseases (Mauro et al., 2008). The fifth edition of the Diagnostic and Statistical
Manual (DSM) recognized substance addiction as a disorder, whereas the prior DSMs classified
addiction as substance dependence or substance abuse (American Psychiatric Association
[APA], 2013). Classifying opioid addiction as a disorder is meaningful because it recognizes the
patient’s inability to stop using the substance without help. Insurance companies are now much
more likely to pay for treatment for a clinically diagnosable disorder.
Treatments for substance use disorders, especially opioid use disorder, have progressed
rapidly over the last 20 years. Other medicated assisted treatments include Suboxone, Subutex,
Antabuse, Campral, methadone, and Vivitrol. Some of these treatments are relatively new.
Suboxone was approved by the FDA to treat opiate addiction in 2002, methadone in the 1960s,
and Vivitrol in 2017 (FDA, 2019). Treatments for those with co-occurring disorders can consist
of substance use treatments in conjunction with psychiatric medication management, counseling,
or both (Schuckit, 2006).
Although methadone has been present for decades, it has been used more prevalently
only over the past ten years (BSAS, 2017). It remains a treatment that is not utilized in balance to
the opiate epidemic because there is controversy, skepticism, and fear surrounding the nature of
the treatment. Long-term effectiveness of methadone treatment has not been widely studied, nor
has this been studied greatly as a treatment for those with co-occurring disorders.
Methadone maintenance treatment (MMT) was developed in 1964. It was created in
response to the heroin epidemic that followed World War II, given in doses from 80 mg to 120
mg (Moskalewicz & Welbel, 2013). As methadone works in the same fashion as heroin,
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presumably, the patient would not get sick from withdrawal symptoms, and therefore, would not
feel the need to use heroin any longer. This was thought to quell opioid cravings. It was
eventually given to pain clients as it is a synthetic opioid and works in the same fashion as an
illicit opioid or opiate (Joseph et al., 2000).
Methadone was initially looked upon by the general public with disdain and still is in
many sectors because it is a replacement opioid and not addressing a cure for the disease of
opioid addiction (Dole, 1988). Proponents for MMT argue that it keeps clients from risky
behaviors such as sharing needles, prostitution, and street violence, as well as reducing the risk
of overdose. Opponents argue that it is a taxpayer-funded way for patients to continue to illicit
opioid use and to obtain substance for free, without ever obtaining true sobriety or overcoming
the issue of addiction (Dole, 1988). This appears to imply that MMT clients are not using it to
get well but to continue in their addiction for free.
Over the years, many facets of MMT have proven original theories about the treatment
wrong. For example, in the earlier years of MMT, the minimum dose that was thought to have
any effect was 80 mg (Moskalewicz & Welbel, 2013). Now, clients are often treated with as little
as 10 mg in some cases (D’Aunno et al., 2019). It was also initially thought that clients could
easily wean themselves off MMT when it was deemed appropriate and that it was not as
addictive as heroin (Joseph et al., 2000). It is now known that MMT is, arguably, more addictive
than heroin, and it takes a very long time to comfortably wean off MMT (Bale et al., 1980). For
example, many clinics only offer a methadone dose of 1 mg per week or less, which could take
clients, even on a low dose of methadone, a very long time to comfortably wean off (Bransetter
et al., 2008).
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Some feel that it is very dangerous and is slowly becoming another substance to add to
the drug trade (Keary et al., 2012). These opponents declare that it is irresponsible to prescribe
methadone to clients as it enables and encourages their addiction. It has become a common
substance available to be bought and sold illicitly on the streets in many areas. Many proponents
feel that MMT is the answer to heroin addiction and should be made more easily available to a
broad range of providers, administers, and clients (BSAS, 2017).
Problem Statement
Few studies investigated the effectiveness of MMT and non-MMT opiate treatments,
such as intensive outpatient programs, individual and family counseling, psychoeducational
groups, support groups, and psychiatric medication management. This is especially true for those
who need treatment for a co-occurring disorder. Part of the rationale behind this appears to be
that it is hard to measure what is, and what is not, proof of effective treatment. It is
hard to measure accurately what constitutes a successful treatment episode (Drake et al., 2004).
The co-occurrence of a substance use disorder with a mental health disorder is very
common. The addiction issue is the first issue treated, due to the risk of overdose and the severity
of withdrawal symptoms. The imminence of treating the physical addiction often overshadows
the importance of treating the mental health issues that are also present, and the mental health
treatment is put off. When this happens, the client may become stuck in a revolving door of
relapse. The same thing appears to happen in the research of treatment effectiveness for those
with addiction. The importance of addressing those with a co-occurring disorder is overlooked,
and the addiction is the only aspect studied. These studies do not offer an accurate representation
of treatment effectiveness because appropriate treatments might not have been utilized.

15
Another problem is that most studies measure effectiveness by the client’s initial
abstinence from opiates. Many clients who participate in treatments do not wish to participate in
studies. Numerous clients are lost to follow up, and many simply disappear from treatments for
unknown reasons. This fact makes it difficult to determine the number of clients who have
relapsed or the number of clients who stopped coming to treatment when they are feeling better
and moving on with their lives healthily (Farabee et al., 2016).
Clients need to be followed past the point of their initial date of sobriety, for those with a
co-occurring disorder and for those with opioid use disorder only, because the goal of substance
use treatments is, all the same, to assist the client in gaining permanent sobriety. It needs to be
known whether these treatments are helping the clients to stay clean and sober over a long period
or they are relapsing immediately following treatments. If they continue to relapse in large
numbers following a particular type of treatment, the treatment should not be offered as a viable
treatment option. Not many studies have followed their participants all the way through to
ascertain whether they have remained sober following their initial abstinence. It is difficult to say
that a treatment is effective if it is only scrutinized while the medications are being initially
administered. Opioid addiction is not simply a medical condition; it affects all aspects of the
client’s lives. Relationships issues, life skills, social skills, mental illness, housing, sexual issues,
familial issues, and maternity and paternity issues all come along with opioid addiction for
almost all with opioid addiction and co-occurring disorders (De Maeyer et al., 2013).
Still, another weakness of existing studies is that treatments receive much more scrutiny
at the beginning of implementation. Most of these studies focused on the medical implications of
the treatments: What receptors were affected and how the treatments would affect the brain.
Theories that appear to drive most of these studies are medically-based, explaining the
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physiology of how treatments work. Aspects other than medically substituting opioids or getting
the client to somehow stop using them are not normally followed up with checking into the
client’s recidivism in treatment or success in aftercare treatment.
The problem with existing studies is that we do not have a comprehensive definition of
effective treatment, we do not know if MAT is more effective than other types of treatment, and
we lack any information on long-term abstinence which would indicate treatment success. Which
treatments truly work best for long-term sobriety for those with opioid use disorder and cooccurring disorders?
Purpose Statement
The purpose of this study is to determine the long-term effectiveness of MMT and nonmethadone treatments alone and in conjunction with other treatments for those with opioid use
disorder and co-occurring disorders. Effectiveness is defined to include completion of treatment
and non-recidivism within one year. Opioid addiction and co-occurring mental health disorders
have been proven to have very high recidivism rates. It is crucial to determine what treatments
are most effective for this population in the long term. As previously established, there has not
been much research on the lasting effectiveness of MMT for opioid abusers and those with a cooccurring disorder (Fei et al., 2016; Kampman & Jarvis, 2015).
This study examined archival data from 1,000 records over one year of treatment. The
record was analyzed from the start date of each record to 12 months after each treatment episode.
These records were chosen from the archival database at a substance abuse and mental health
treatment center in Massachusetts. All participants have been diagnosed with opioid use disorder.
Half of them have additionally been diagnosed with a co-occurring disorder. Records were
randomly chosen until 1,000 records representing different categories of treatment are obtained.
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Non-MMT clients were treated with individual counseling, psychoeducational groups, support
groups (such as Narcotics Anonymous), intensive outpatient, family intervention programs,
partial hospitalization, residential treatment (half-way house, sober house), other medicated
assisted treatments (Suboxone, Subutex, Antabuse, Campral, Vivitrol), and psychiatric
medication management for those with a co-occurring disorder.
Of the one-thousand clients receiving outpatient treatments, those with co-occurring
disorders and those without were chosen at random. Because the aim of the study is to determine
the effectiveness of outpatient treatments in comorbid and non-comorbid patients, it was
important to study the effects of those who were using one treatment only and those who were
using more than one treatment. This helps to determine whether one treatment is sufficient for
those with opioid use disorders and co-occurring disorders or it is more effective to use a
treatment in conjunction with other treatment methods. For this reason, clients were chosen at
random for those who were using one treatment only and those who were receiving more than
one treatment simultaneously. The same was true for those without comorbidity and the nonMAT groups.
Success was measured in the completion of treatment. Completion of treatment was
defined as those who remained in treatment for 1 year following initially obtaining sobriety,
were transferred to another treatment program due to relocation of residence or graduating to a
lower level of care, or were weaned off treatment properly in accordance with their treatment
plan. Unsuccessful treatment was measured by those who relapsed, died by overdose, or left
treatment due to other factors, such as administrative discharge (being removed from the
program) due to violence at the program, threatening behavior at the program, having positive
urine drug screens, or incarceration.
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This study resolves the shortcomings of existing studies by comparing the long-term
efficacy of OUD treatments. It also examines long-term outcomes of substance use disorder
(SUD) treatments for those with opioid use disorder, as well as long-term outcomes for those
with co-occurring disorders receiving SUD treatments. Finally, it examines the efficacy of OUD
treatment alone, as well as in conjunction with other treatments.
Significance of the Study
This study contributes to the knowledge of the effectiveness of substance abuse
treatments including methadone and non-methadone treatments for clients with and without cooccurring disorders in a way that would assist clinicians in helping clients to choose which
outpatient treatment is the right treatment choice. It is not only important to know which
treatments help the client to abstain from opioid use immediately and in the short term, but to
know which treatments are effective in helping the client to remain sober (Bart, 2012). The goal
for every client is to eventually live a happy and healthy life, which can only be achieved if they
can stay sober (Stanbury, 2014). This study evaluates whether MMT or non-MMT are effective
for clients to remain clean and sober (Nabipour et al., 2014). The data that was researched in this
study can be shared with treatment facilities to assist them in effectively informing clients of
appropriate treatment options for them without only being able to offer personal opinion of what
they consider to be effective. This study also offers insight into the controversy previously
discussed concerning the long-term effectiveness of methadone maintenance as a treatment.
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Research Questions
RQ1: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with MMT?
RQ2: Is there a statistically significant difference between expected and actual success rate in
those with opioid use disorder when treated with Suboxone?
RQ3: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with Vivitrol?
RQ4: Is there a statistically significant difference between the expected and actual success rates
in those with opioid use disorder when treated with individual counseling?
RQ5: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with group counseling?
RQ6: Is there a statistically significant difference between the expected and actual success rates
in those with opioid use disorder when treated with intensive outpatient (IOP)?
RQ7: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with psychiatry?
RQ8: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with family intervention?
Definitions
1. Successful treatment: one year of continued sobriety beginning at the start of treatment.
2. Recidivism: relapse into opioid use.
3. Co-occurring disorder: When a client is diagnosed with a mental health disorder and a
substance use disorder.
4. Expected outcome: the quantitative outcome that is predicted.
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5. Psychiatry: the study and treatment of mental illness, emotional disturbance, and
abnormal behavior.
6. Individual counseling: counseling conducted on a one to one basis.
7. Group counseling: counseling and education conducted with one facilitator and multiple
clients.
8. Family intervention: families intervening in a client’s life to assist them in getting
treatment for a substance use disorder.
9. IOP: a treatment modality where clients attend group and individual counseling for up to
6 hours a day, 3–5 days per week.
10. Counseling: guidance to assist in resolving social, psychological, and personal problems.
Summary
There are different options for the treatment of opioid use disorder and co-occurring
mental health disorders. It can be difficult to determine which treatments are the best option for a
patient seeking treatment. Part of the reason is that it is difficult to determine what constitutes an
effective treatment and to keep track of patients after they leave treatment. This study attempts to
define a successful treatment episode and compares different treatment modalities to each other
to determine under what conditions are different opioid use disorder treatments effective.
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CHAPTER TWO: LITERATURE REVIEW
Overview
Opioid addiction can stem from hereditary or environmental factors (Barry et al., 2014).
One of the issues with opioid use is the fact that sometimes people who use them become
physically addicted before they realize that it has happened (Herz & Shippenberg, 2012). Opioid
addiction is very difficult to overcome due to neurochemical addiction (Herz & Shippenberg,
2012). By this time, the issue is out of control and the addiction begins to affect all other aspects
of the person’s life: Relationships suffer and daily activities begin to revolve around substance
use. Quickly the person’s life, inevitably, ends up in shambles. This can lead to crime and risky
behaviors. This makes it extremely important to help those with addictions to heal. To do this
treatment, providers must know the most effective treatment methods. The goal of treatment
should be to help the client to get well for the rest of their life, not just in the near future.
There are different treatment methods for those with opioid use disorder. Some include
medication treatments, some include therapies and education, as well as residential programs and
family involvement (Saloner & Karhtikeyan, 2015). Treatments for those with mental health
comorbidity usually include therapies and possibly medications (Saloner & Karthikeyan, 2015)
and may be more intensive than those without comorbidity. MMT is a very popular outpatient
treatment for those with opioid use disorder (Ball & Ross, 2012).
When treating opioid addiction, many options are available to the client. Over the past
few years, it appears that MMT is the most utilized option for outpatient opioid use disorder
treatment for those with and without co-occurring disorders (National Institute on Drug Abuse
[NIDA], 2019). This writer has studied the benefits and disadvantages of MMT. It became
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important to ascertain whether MMT is truly the most effective treatment option or other options
are more effective. Thus, it became important to study this topic.
This literature review was conducted through searching the key phrases methadone,
MMT, medicated assisted treatments, co-occurring disorders, history of substance use
treatments, history of heroin, chemical composition of opiates and opioids, substance addiction
treatments, effects of addiction, and long-term outcomes of substance abuse treatments. These
searches were completed in the Liberty University online library, Google Scholar, and
Mendeley, as well as researching the leading national agencies on substance abuse and treatment
for those with SUD and co-occurring disorders. The references from particular informative
articles were used to find additional sources on the searched topics.
Conceptual Framework
Maslow’s Hierarchy of Needs proposes that all humans have basic needs that must be
met for them to thrive (Mathes, 1981). Many needs can be measured on a case-by-case basis, but
Maslow identifies the essentials that all needs as building blocks to a happy fulfilling life. These
needs are physiological, safety, security, love, belonging, self-esteem, and self-actualization
needs (Mathes, 1981). Physiological needs consist of air, water, food, sleep, clothing, and shelter
(Mathes, 1981). Safety and security needs contain personal and financial safety, health and wellbeing, and safety against illness and injury (Mathes, 1981). Love and belonging needs consist of
friendships, intimacy, and family (Mathes, 1981). Self-esteem needs include feeling important to
and respected by others (Mathes, 1981). Self-actualization refers to a person recognizing their
potential and reaching that potential (Mathes, 1981).
Sometimes, individuals use substances due to an inability to have these needs met. For
instance, those who never learned how to establish a loving relationship with others have
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difficulty cultivating relationships; therefore, they turn to substances to either numb this need or
to give them synthetic courage to seek out to fulfill these needs. Those who have severe anxiety
and cannot stop worrying about the affairs of the world use substances to quell their nervous
feelings and feel safe and secure. Many substance addictions are developed due to reasons such
as these.
This explanation of basic human needs is the basis of why treatment is provided to those
with substance addiction and mental health problems. The goal is to help patients to experience
these necessities so they can obtain fulfillment and happiness. Humanistic treatment methods can
be so important in these instances. If the client becomes clean and sober but never addresses their
human needs, relapse is inevitable. Some treatment methods could include counseling and
support groups. When an individual has a substance addiction or a co-occurring disorder, one or
more, if not all, of these needs can be interrupted or lost by the individual as a direct result of
their addiction.
The conceptual framework for this study is the basis to determine whether MMT is the
best treatment method to give clients with opioid use disorder and co-occurring disorders the best
chance of thriving and obtaining their basic needs. It examines the effects of methadone
treatments on opiate addiction and co-occurring disorders, as well as non-methadone treatments
for opiate addiction and co-occurring disorders. The focus is placed on methadone as it is the
most widely used medicated assisted treatment for those with opioid addictions (BSAS, 2017).
This is achieved by evaluating one-thousand clients who utilized methadone maintenance and
non-methadone treatments, and their outcomes over one year. Expected outcomes are predicted
based on previous research. The expected outcomes for those who utilized methadone
maintenance for treatment are under a 50% success rate (Maremmani et al., 2018). This
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information is gathered from the archives of a substance use treatment facility in Massachusetts
from the time of 2016 to 2017.
Theoretical Causes of SUDs
Substance use disorders usually have precursors, or risk factors, that can contribute to
their development. Some are genetic, substance abuse trickling down from generation to
generation (Swendsen et al., 2009). Many are environmental, including what happens in the
household of upbringing, such as abuse, trauma, or substance use (Swendsen et al., 2009). Many
times, precursors include environmental and genetic factors, which gives the individual an even
greater chance of succumbing to SUD (Agrawal & Lynskey, 2008). The neighborhood in which
one was raised and the circle of friends and acquaintances with whom one associate can be
another precursor (Banducci et al., 2014). Although a family history of substance abuse and
addiction does not guarantee the positivity of addiction in the next generation, there is a very
high rate of those who have a substance abuse disorder having a family history of the same
(Banducci et al., 2014).
Genetics can play a role in the cause of SUDs (Swendsen et al., 2009). The human
genome contains units of DNA, which direct cellular activities (NIDA, 2019). Families can share
many of these DNA sequences. Therefore, families often look alike, sound alike, or move alike.
This is also why certain diseases and traits can be passed down from generation to generation.
The same can be true for a person’s increased risk for, or protection against, addiction (NIDA,
2019). If someone is an alcoholic, their children could be much more likely to become addicted
to alcohol, if consumed, than someone who did not inherit these genetic traits (NIDA, 2019).
This does not mean that it is inevitable that their children will become alcoholics, just that they
could be predisposed (NIDA, 2019).
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Theories Behind Treatment
When treating those with SUDs, several evidence-based psychological and psychosocial
treatments are usually employed. Cognitive-behavioral treatments are utilized to curb behaviors
that lead to drug use and its associated activities (Osher & Drake, 1996). These treatments
include brief intervention, CBT, Motivational interviewing, relapse prevention, and contingency
management (Jhanjee, 2014). Other treatment modalities include therapeutic communities,
residential treatment, and support groups, including Alcoholics Anonymous and Narcotics
Anonymous (Jhanjee, 2014).
Social control theory indicates that motivational factors utilized in the treatment of
substance abusers include several different factors (NIDA, 2019). These often include family and
friend relationships, parental responsibility, school, work, and religion, as well as other aspects
of traditional society (Jhanjee, 2014). A good collaborative treatment plan includes familial
support if available, peer support in the form of outpatient group therapy and support groups, as
well as obtaining a sponsor, and securing employment to fulfill a sense of purpose (Drake et al.,
2004).
As related to addiction, harm reduction theory puts forth the notion that allowing those
who participate in risky behaviors associated to their drug use, such as prostitution, using dirty
needles, sharing needles, overdose, and violence, would be safer if supervised while using
substances (Wermeling, 2010). Harm reduction treatment methods do not cure the individual
from their physical addiction but offer them a safer alternative to using street drugs (Hawk &
D’Onofrio, 2015). These methods can help to avoid overdose and disease transmission. Practices
in harm reduction include methadone maintenance, Suboxone maintenance, providing clients
with clean needles and bleaching kits, and opioid injection sites (Jhanjee, 2014). Opioid
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injection sites are places where individuals can take opioids under supervision (Wermeling,
2010). This is thought to be safer so the person is supervised while they are under the influence
so that nothing bad would happen to them, and there is someone there to treat them in the event
of an overdose (Wermeling, 2010).
Exposure theory deduces that a cause for addiction can be exposure to substances through
no fault of the individual’s (jointcommision.org). This includes instances such as fetal exposure
in utero (jointcommision.org). Substance exposed newborns might have a higher risk of future
addictive tendencies than those who were not exposed to substances (jointcommision.org). This
can also apply to patients who were given opiates as a prescription to treat pain after illness or
injury (jointcommision.org). There are also a number of those with an addiction who were given
substances by their parents or older peers at a very young age (Swendsen et al., 2010). These
scenarios can put the individual at great risk of developing a substance addiction.
Social learning theory contends that people are greatly affected by their families, peers,
and communities (Akers et al., 1989). Individuals learn by observing. If a child observes that
their father copes with stress by drinking, they learn that this is an acceptable coping mechanism.
If they observe that friends have fun by smoking marijuana, they learn that a positive result
comes from smoking marijuana. If a person becomes an addict, slowly over time their entire
circle will become others who employ the same lifestyle (Akers et al., 1989). Interactions with
healthy family and friends will dissipate and addiction becomes more accepted as the norm. This
theory contends that 55% of adolescent substance abuse begins in this way (Akers et al., 1989).
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Related Literature
Substance Use Disorders
Neurochemical addiction occurs when a person develops a tolerance to, as well as a
dependence on, opioids or opiates (Herz & Shippenberg, 2012). This happens when the reward
pathways in the brain are activated (Herz & Shippenberg, 2012). The neural system motivates
the user to ensue with substance abuse and releases pleasure hormones (Herz & Shippenberg,
2012). Once the drug dependence has been created, it must be maintained or the brain releases
physical and emotional cues to encourage the continued feeding to the reward pathways (Herz &
Shippenberg, 2012).
Opioids affect the brain’s communication system. The way that the brain sends and
receives messages to itself, as well as how it processes information, is affected by different types
of drugs (Herz & Shippenberg, 2012). Some drugs activate neurons while some inhibit them
(Kreek et al., 2010). These effects can sometimes be permanent depending on the severity and
length of the substance abuse (Kreek et al., 2010). The cognitive abilities of the brain can be
decreased, as well as the memory, on a permanent or temporary basis (BSAS, 2016).
Drugs can also affect neurotransmitters such as dopamine and serotonin levels in the
brain (Fischer & Ullsperger, 2017). Dopamine is a chemical that is produced in the brain to send
messages to the limbic system (Fischer & Ullsperger, 2017). Serotonin acts in much the same
way (Cools et al., 2011). These are chemicals that increase mood and increase feelings of
pleasure and euphoria (Seo et al., 2008). Other brain chemicals that are affected by drug use are
gamma-aminobutyric acid (GABA) and glutamate, which is a neurotransmitter that calms
nervous activity, and norepinephrine, a neurotransmitter that affects how the body reacts to stress
(Manchikanti, 2007).
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Stimulants, such as cocaine and crack, affect dopamine and serotonin (Sora et al., 2001).
They cause an excessive release of more dopamine than normal, thus producing a euphoric effect
(Sora et al., 2001). Depressant drugs (alcohol, benzodiazepines, barbiturates, and others)
suppress GABA and glutamate (Piepponen et al., 2002). This keeps the nervous system from
being excited. Opiates bind to endorphin receptors (Bond et al., 1998). When these receptors are
activated, they reduce physical pain (Bond et al., 1998). Therefore, opiates are prescribed for
injuries and after surgeries. Drugs such as OxyContin and Percocet have the same effects as
heroin (Evans, Lieber, & Power, 2019).
Physical, Cognitive, and Emotional Effects of Addiction
Physical problems caused by substance abuse include sleep problems, appetite issues,
increased or decreased heart rate, high or low blood pressure, abnormal respiration, and chest
and lung pain (Brick, 2012). Weight loss or gain is also a potential side effect (Brick, 2012).
Long-term brain damage can occur, which is irreparable (Brick, 2012). Substance abuse
frequently affects some areas of the brain that control sleep, learning, memory, and emotion
(Gruber et al., 2007). Substance use can also cause degenerated nerve endings (Manchikanti,
2007).
Some drugs are psychoactive; they have a profound or significant effect on mental
processing (Dictionary, 2016). These include alcohol, certain amphetamines, heroin, and
marijuana (Julien, 2013). They can either heighten emotions or act as depressants (Julien, 2013).
Long-term use of these drugs can permanently damage the brain’s ability to recognize and
exhibit emotion normally (Schiavone, Neri, & Harvey, 2019).
Some other health concerns associated with drug use can be heart attack, stroke, kidney
and liver damage, seizures, cancer, and breathing problems (Julien, 2013). Certain diseases are
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also associated with drug use. Commonly spread diseases with drug users are Hepatitis C and
Human Immunodeficiency Virus (Friedman et al., 1993; Harris et al., 1993). These have a higher
likelihood of transmission depending on the route of administration (Des Jarlais et al., 1989).
Intravenous users have a higher likelihood of contracting these communicable diseases
(AMA.org, 2013).
Excessive drinking can damage the liver. The liver processes and breaks down harmful
substances (Leiber, 1994), including alcohol. When the liver has been breaking down excessive
amounts of alcohol over a long period of time, it causes damage to the liver (Leiber, 1994). Thus,
the liver stops functioning properly. A common sign of a damaged liver is yellowing of the skin,
which is called jaundice (Rajagopal, Sangam, Singh, & Joginapally, 2015). Chronic
inflammation of the liver can result in cirrhosis, which is a deterioration of the liver and can be
fatal (Califano et al., 2001).
Diagnostic Criteria for a Substance Use Disorder
The following symptoms are used to diagnose SUDs: use more than intended,
unsuccessful attempts to reduce usage; daily activities revolving around obtaining and using
substance; craving; use causing significant impairment or distress resulting in failure to fulfill
work obligations, school obligations, and home obligations; recurrent substance-related legal
problems; withdrawal from family or friends; withdrawal or reduction in recreational
activities/hobbies; recurrent use driving operating machinery; increasing dosage to achieve the
desired effect; markedly reduced effect when the usual dose is used; presenting symptoms as
blood or tissue concentration declines; and using substance to relieve withdrawal symptoms
(APA, 2013).
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If a client were to be specifically diagnosed with opioid use disorder, they would be
diagnosed with some of the following symptoms: opioids taken in larger amounts or over a
longer period than intended, unsuccessful attempts to cut down on use, a great deal of time is
spent in obtaining opioids, a great deal of time is spent recovering from the opioids effects,
cravings or a strong desire to use opioids, recurrent opioid use resulting in failure to fulfill life
obligations, continued use despite having interpersonal problems resulting from use, important
activities given up or reduced as a result of use, recurrent use even when it is in a hazardous
situation, continued use despite having a physical or psychiatric problem as a result of use,
tolerance to opioids, and withdrawal symptoms when opioids are not used (APA, 2013). It is
important to note that this diagnosis is not meant for those taking opioids for pain appropriately
under medical supervision.
Specifiers
A client must meet 2–3 of these symptoms to be classified as mild opioid use disorder
(APA, 2013). They must meet 4–5 of these symptoms to be classified as having a moderate use
disorder, and six or more symptoms would indicate a severe opioid use disorder (APA, 2013). In
addition to specifying severity when diagnosing an opioid use disorder, the clinician must
specify remission (APA, 2013). If a client is on methadone maintenance, the diagnosis should
contain a specifier of “on agonist therapy” (APA, 2013). For one on Suboxone maintenance the
specifier should be “on partial agonist therapy,” and for those on Vivitrol maintenance, the
specifier should be “on ant-agonist” therapy (APA, 2013).
There are also specifiers for those who are in remission and are not using any medicated
assisted therapies (APA, 2013). These include in early remission for those who have been clean
for 4–11 months, in partial remission for those who have had up to 3 months of sobriety, or have
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had a long-term remission spotted by a few times of usage, and in sustained remission for clients
who have remained clean for 1 year or more (APA, 2013). Those who have remained sober for
over one year will receive a different diagnosis and diagnosis code of opioid use disorder in
sustained remission, F11.21, while all other opioid use disorders have a diagnosis code of F11.20
(APA, 2013).
Potential Causes for Substance Abuse
Trauma History
Studies have been conducted to ascertain whether depression is a clear indicator of
substance use among juveniles (Lo & Cheng, 2007). This study implies that depression appears
to be a mediating or moderating factor between childhood physical and sexual abuse and
adulthood substance abuse (Friedman et al., 1993). This might indicate the use of substances to
self-medicate depressive symptoms, which may have stemmed from childhood trauma (Lo &
Cheng, 2007). It appears that childhood stressors are a common precursor to SUDs.
Many who suffer from substance abuse begin using substances to self-medicate
symptoms arising from mental health or trauma issues (Garland, Pettus-Davis, & Howard, 2013).
If a person suffers from depression, anxiety, or more serious mental health issues, illicit
substances can seem to be a quick and easy way to numb emotional distress (Garland, PettusDavis, & Howard, 2013). This is especially true since the mental health profession is inundated
with those who need treatment, and many are forced to go without getting the help that they need
(Kohn et al., 2004).
Waiting lists for a mental health treatment provider can be very lengthy and can take
months to get appointments. When an appointment is obtained, it can be additional months to
figure out the best treatment to help the individual (Sussman et al., 2008). Additionally, once the
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client is addicted to a substance, it is difficult for them to remain faithful to their mental health
treatment, and a lack of mental health treatment can create a vicious cycle (Kohn et al., 2004).
Thus, the unavailability of mental health treatment is a common factor in substance addiction
(Mojtabi, 2011).
Those who have suffered through childhood trauma often suffer from mental health
issues such as post-traumatic stress disorder and reactive attachment disorder (Everett and
Gallop, 2000). They often struggle with relationships due to having trust issues (Everett et al.,
2000). The effects of childhood trauma often ruin people’s adult lives (Edwards et al., 2003).
Using substances in order to numb any unpleasantness happening in one’s life is a common
reason given for why individuals began using illicit substances (Sussman et al., 2008).
Familial Factors
Substance abuse appears to be a multigenerational issue (Goldberg & Gould, 2019).
Children of substance abusers are more likely to become substance abusers themselves
(Goldberg & Gould, 2019). Substance use becomes a normal occurrence and does not feel out of
the ordinary to those who have parents who used substances (Kreek et al., 2005). They are also
more likely to suffer in other areas of their lives, including their social environment. Initially,
substance abuse in a family affects the overall functioning of the family (Mayes & Truman,
2002).
Sometimes, parents who are substance abusers encourage their children to do the same
(Kelleher et al., 1994). A reason given by some who have encouraged their children to abuse
substances was that it was more fun to use with a partner, and they wanted their children to have
fun with them (Pears et al., 2007). It can also be due to the irresponsible and consuming nature of
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substance abuse, which can cause the parent to not be careful in keeping their abuse issues from
their child (Barnard & McKeganey, 2004).
Environmental Factors
Environment is, undoubtedly, a factor in substance abuse addiction (McLeod et al.,
2004). For those who either grow up in a particular type of environment or reside or socialize in
a type of environment, desensitization is inevitable (McLeod et al., 2004). When substance use
does not feel like something out of the ordinary, it can easily become a normal occurrence in
one’s life. If a person’s friends are frequently engaged in a certain activity, it becomes easier for
one to become involved in the same activity (Kendler et al., 2003). This is especially true if the
activity appears alluring, which substance use often does in the beginning. The long-term
consequences are not always evident.
Another environmental factor that has been recently described as a public health crisis is
the overprescribing of opioid pain relievers (Kolodny et al., 2015). This has shown itself to be a
prominent gateway to an opioid use disorder. An increase in patients becoming addicted to
prescription opioids has led to illicit Percocet and Oxycontin addictions, which often turn into
heroin addictions as it is cheaper on the streets than opioid pills (Kolodny et al., 2015). From
1999 to 2011, the prescribing of opioid pain relievers increased by 500%, and the number of
overdose deaths related to prescription opioids quadrupled (Kolodny et al., 2015).
Treatment Modalities for Opioid Use Disorder
Some modern substance abuse treatment models base their methods of treatment on
social learning theory, meaning that the social context of the person’s use is considered in their
treatment planning (Peralta, & Steele, 2010). Social influences are all considered when trying to
determine the precursors of the client’s substance use issues and the proper level of care for the
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client (Litt, 1996). Other modalities base their methods on medical interventions, such as
methadone maintenance or Suboxone maintenance (Sittambalam et al., 2014). Some modalities
base their methods on emotional and educational treatment methods including individual therapy
and group treatment (McGinty et al., 2015). Many treatment options are available to those who
are searching for help to end their substance abuse issues.
Non-Medicated Assisted Treatments
Outpatient treatment includes substance abuse counseling, family counseling, intensive
outpatient programs, partial hospitalization programs, psychoeducational groups, support groups,
residential treatments including half-way houses, sober houses, and therapeutic communities.
Treatment is not the same for every client. Each client must be assessed for the most appropriate
level of care that will provide them the best individual outcome. This is determined based on the
client’s substance addiction severity, life situation, and client choice.
Intensive Outpatient
IOP programs combine individual therapy with group psychoeducation, as well as peer
support (Gruber et al., 2007). Clients can attend the program anywhere from three to 12 weeks
(Gruber et al., 2007). This program is encouraged for clients who have been detoxed and
stabilized on any medications that they might need for those with co-occurring disorders (Gossop
et al., 1986). Clients are usually advised to attend this program for 3–6 weeks, and then follow
up with slightly less intensive treatment (Blackmore, 2006).
Substance Abuse Disorder Counseling
SUD counseling is an approach in which clients should participate regardless of the type
of treatment they are receiving (Furst, 2013). Following detoxification, the client’s brain takes a
minimum of one year to even begin to start to process things in the way that a normal brain does
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(Talmadge, 2010). It can take this long or longer, depending on the amount of damage that has
been done to the brain (Talmadge, 2010). This is usually determined by the amount, type, and
length of time the substance is used (Urschel, 2009). The client would need intensive and
continual support, as well as instruction on how to cope with everyday stressors (Kaiseler et al.,
2009). Not only is there a strong probability that the client does not have appropriate coping
skills due to reliance on substances for so long, but they also have probably not dealt with
normal, everyday life for this duration. Many relapses are due to stressors that others would
consider to be normal life stressors.
Individual Counseling
Individual counseling is an approach that all clients who have an opioid use disorder or a
co-occurring disorder can benefit from, and is strongly encouraged for, all in recovery. Family
support and peer mentoring are other forms of treatment for those who are in newfound recovery.
Those who have a support system in their personal life have a much higher chance of
maintaining their sobriety long term (Lorman, 2013).
Exercise as a Part of Outpatient Treatment
In outpatient treatment, clients are usually advised to incorporate exercise as a part of
their collaborative treatment program (Gold, 1993). The human brain and pituitary gland create
endorphins as a result of physical activity (Maldonado, Dauge, Callebert, Villette, FournieZaluski, Feger, & Roques, 1989). The word endorphin comes from Greek, and literally means,
“The morphine within.” (Maldonado, Dauge, Callebert, Villette, Fournie-Zaluski, Feger, &
Roques, 1989). Endorphins, which belong to a family of chemical compounds called peptides,
act in a similar way as opiates in the brain (Maldonado, Dauge, Callebert, Villette, FournieZaluski, Feger, & Roques, 1989).
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Some scientists believe that natural endorphins hold the key to effective treatment of
many mental illnesses and SUDs (Maldonado, Dauge, Callebert, Villette, Fournie-Zaluski,
Feger, & Roques, 1989).
There have been specific instances of those who were prisoners of war and being tortured
daily, who reported not physically feeling the pain (McFarlane, 2010). It is thought that this is a
type of endorphin response that the brain creates to protect the body (Maldonado, Dauge,
Callebert, Villette, Fournie-Zaluski, Feger, & Roques, 1989). There is some belief that
endorphins are so powerful that they can assist in natural childbirth (Maldonado, Dauge,
Callebert, Villette, Fournie-Zaluski, Feger, & Roques, 1989).
Because exercise releases natural endorphins, it is recommended in any type of holistic
treatment plan (Lynch et al., 2013). Releasing natural endorphins gives a natural, healthy way to
help control cravings and maintain sobriety (Brown et al., 2010). Some even recommend raising
endorphins as a way of detoxifying naturally from illicit substances with no comfort medications
utilized (Lorman, 2013). Exercise can greatly assist a client in obtaining sobriety and needs to be
utilized in conjunction with other treatments.
Religiosity/Spirituality as a Part of Outpatient Treatment
Spirituality is a large part of substance abuse counseling, intensive outpatient programs,
support groups such as NA (Narcotics Anonymous) and AA (Alcoholics Anonymous), and
mental health counseling (Arnold et al., 2002). The very principles of AA, the 12 steps, are based
on spirituality (Arnold et al., 2002). Spirituality appears to insulate against substance abuse to a
certain extent, as those who consider themselves to be religious begin using illicit substances on
a less frequent basis than those who do not consider themselves to be religious (Pardini et al.,
2000). In addition, those who consider themselves to be religious, but use substances anyway,
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reported that social bonding with other religious people helped them to remain sober (Pardini et
al., 2000). Those who were not religious or spiritual had a higher rate of illicit substance use than
those who were religious or spiritual (Allen & Lo, 2010).
Giordano et al.’s (2015) study showed that religiosity has an inverse effect on the
students’ likelihood to drink alcohol or use marijuana. Coping skills that are obtained through the
individual’s spirituality appear to influence abstaining from substance abuse (Giordano et al.,
2015). Religiosity does not appear to make a difference in students’ use of stimulants and
benzodiazepines (Giordano et al., 2015).
Mason et al. (2009) conducted a study on men between the ages of 19–74 who had
treatment at the Australian Salvation Army. About 75% of the participants reported that religion
helped them in their recovery (Mason et al., 2009). Seventy-eight percent of them had reported
using more than one substance (Mason et al., 2009). The majority of them reported that religious
coping helped them with their level of craving (Mason et al., 2009).
Mindfulness as a Part of Treatment
Scientists have been studying the mind for thousands of years, and still do not have an
accurate grasp on its potential. It is commonly agreed by scientists that only a small percentage
of the mind is utilized (Bowen et al., 2009). Scientists are constantly working to find ways to
assess the extent of the things that the mind can do (Thompson, 2010, pp. 3–65). Mindfulness is
a therapeutic technique where the individual practices focusing on the feelings and sensations of
the present moment to calm the mind (Dictionary, 2016). Mindfulness can be an important part
of individual and group outpatient treatment (Thompson, 2010). Teaching clients to be mindful
equips them to cope with life stressors (Bowen et al., 2009). Studies have shown that using
mindfulness as a relapse prevention and treatment technique has reduced clients’ short term
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relapse and helped those with co-occurring SUD and depression or anxiety to manage their
symptoms and remain clean (Roos et al., 2017).
Mindful thinking can help individuals to cope with stress (Bowen et al., 2006).
Mindfulness is taking note of one’s surrounding to calm the mind, which can be done as daily
stress-relieving ritual or as a calming technique (Bowen et al., 2006). Mindfulness is learning
how to do away with the fight or flight mentality (Holmes, 2009, pp. 36-38). It is responding to a
distressing situation instead of reacting to it (Holmes, 2009, pp. 36-38). Since all of these
symptoms are part of what clients go through in recovery and SUD/co-occurring disorder
treatment, patients can use mindfulness as a coping technique (Tang et al., 2016).
There are health benefits associated with mindfully dealing with stressors (Holmes, 2009,
pp. 36-38). The mind can be trained to effectively cope with stress (Enkema & Bowen, 2017). In
images on an MRI, the gray brain matter increased and the white matter got denser as the client
utilized brainpower to overcome stress (Valkanova et al., 2014, p. 891). In Russia, scientists and
doctors are helping those who have had traumatic brain injuries to heal themselves by training
their minds (Mckelvey & Dornan, 2004, 1459).
Medicated Assisted Treatments
Some theorize that substance abusers have a better chance of initial detoxification with
medicated assisted treatments (Bell & Strang, 2020). Others argue that those who use medicated
assisted treatments are not truly sober (Johnson & Hagström, 2005). There are different types of
medicated assisted treatments.
Suboxone
Suboxone is a combination of buprenorphine and naloxone, usually administered in a
sublingual film (Schwartz et al., 2012). Suboxone is considered a partial opioid agonist, meaning
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that it activates the opioid receptors in the brain, but to a much lesser degree than a full agonist
(Wakhlu, 2009). It is a partial agonist of the mu receptor and an antagonist of the kappa receptor
(Sittambalam et al., 2014, pp. 1–6). Naltrexone in Suboxone makes the client almost
immediately sick if they use opiates, putting them into withdrawals which include nausea,
headache, sweating, vomiting, dizziness, aching limbs, and extreme irritability (Wakhlu, 2009).
This makes Suboxone ideal to assist in withdrawal avoidance and as a deterrent to illicit opioids
used properly.
Buprenorphine in Suboxone keep the client from having cravings and withdrawals if
administered properly (Wakhlu, 2009). This effect keeps the client from feeling sick from the
effects of opiate withdrawals (Finch et al., 2007). It is an alternative to methadone and is usually
available as a take-home product, though with frequent office visits (Finch et al., 2007). This
medication is not as strong as methadone and is thought to be safer (Finch et al., 2007). It does
not have severe side effects for those without an allergy to buprenorphine or naltrexone (Walsh
et al., 1995).
Despite its use as a deterrent, Suboxone does have the potential for abuse. In Furst’s
(2013) study, 14 Suboxone patients admitted to chronically using MAT on again off, while using
opiates in between. They admitted to using MAT cognizantly for their substance abuse habit
(Fusrt, 2013, pp. 53–67). This study appears to confirm that some clients abuse the MAT. Clients
have also admitted to selling their prescription Suboxone for profit, instead of taking them as
prescribed. Other disadvantages with Suboxone treatment include the DPH only providing
waivers to doctors to prescribe to a limited number of patients (McLean & Kavanaugh, 2019),
doctors not receiving proper training on how to educate the patients and how to properly treat a
patient with Suboxone, and illicit drug dealers of prescription medications not being focused on
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as much by police, as they are focused on more traditional illicit substance distribution
(Kennedy-Hendricks et al., 2016).
Subutex
Subutex is buprenorphine without naltrexone (Simojoki et al., 2008, p. 16). It does not
kick the opiates off of the receptors; therefore, it does not cause sickness and withdrawals if the
client uses illicit opiates. Subutex is a partial agonist only (Smith et al., 2007). It is sometimes
given to pregnant women as a heroin replacement (Meyer et al., 2015). In 2003, one-hundred
inpatient patients in drug treatment facilities received Subutex to aid in their detoxification
(Wallen et al., 2006). Ninety percent of them reported equal to or better than detox that they had
had in the past with other forms of medicated assisted treatments (Wallen et al., 2006). From this
overwhelming percentage, it can be concluded that Subutex aids in withdrawal symptoms from
opioids. Subutex is not always a good choice for clients because they get medications that they
can take home with them, and many clients end up selling their prescriptions while continuing to
use substances illicitly (Smith et al., 2007).
Vivitrol
Vivitrol is a monthly injection that is administered to patients who abuse opiates or
alcohol (Syed & Keating, 2013). Vivitrol is an antagonist, meaning that it blocks the opioid
receptors (Syed & Keating, 2013). The effects of Vivitrol last for four weeks (Syed & Keating,
2013). If a client uses alcohol or opiates while Vivitrol is in their system, they become violently
ill with vomiting as it gives immediate withdrawal symptoms (Krupitsky & Blokhina, 2010).
Vivitrol takes away the opportunity to use substances impulsively. A drawback of Vivitrol is that
sometimes an addict will attempt to break through the effects of the Vivitrol and will essentially
take so many opiates that they overdose (Syed & Keating, 2013).
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Antabuse
Antabuse works in the same manner as Vivitrol but is effective for alcohol use only
(O'Farrell et al., 1995). It induces very unpleasant symptoms, including nausea, vomiting,
headache, sweating, confusion, and loose bowels, if the client drinks alcohol (Cvek, 2012). The
drawback to Antabuse is that the patient can choose not to take it if they have the desire to drink
that day. This allows the patient to be impulsive and drink on a day that they have not taken the
medication.
Campral/Baclofen
Campral is another medication that is used for the treatment of alcoholism (Elchisak,
2001). It is meant to help reduce the cravings for alcohol but does not make the patient ill if
alcohol is ingested (Spanagel et al., 2013). Baclofen works in the same manner as Campral but is
used to help control cravings for cocaine (Shoptaw et al., 2003). A drawback to both of these
medications is that the client can decide not to take it day to day if they want to use alcohol or
cocaine that day.
Narcan
Narcan (naloxone) is also available at many facilities for free. Narcan is a medication that
is sprayed into the nasal cavity to bring someone back from an overdose (Li et al., 2018). Narcan
works by expelling the opioids from their receptors, thus putting the client into immediate opiate
withdrawals (Li et al., 2018). Usually, the client does not wake up pleasantly and can become
violent or very agitated immediately. A drawback is that the effects of Narcan only last from 20
to 60 minutes, so the client must be brought to the emergency room for follow-up treatment or
they could fall back into their overdosed state (Cools et al., 2011).
Methadone
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Methadone is a manufactured opiate that was originally intended for use with pain
sufferers (Fischer et al., 2005). It then began being used for opiate addicts to potentially help
them to wean off opiates comfortably over time (Fischer et al., 2005). In the 1970s, it re-emerged
as a pain therapy (Chary, 2018). It was created in the 1950s synthetically (Chary, 2018). and
began being used to treat opioid addiction in the 1980s (White, 1998).
Methadone is a full agonist, meaning that it activates the opioid receptors in the brain,
giving the full-opioid effect (Mattick et al., 2009). Other full agonists include heroin, oxycodone,
morpheme, and opium (Joseph et al., 2000). When using MMT, the dose administered to the
client is reduced gradually, usually about 5 mg per week but this can vary from a clinic to
another. Although many have been able to titrate off MMT in the six-month time frame, many
are unable to obtain success over such a short amount of time (Gossop et al., 2001). Many
patients report that the period that it took for them to slowly come down on their methadone dose
was longer than they had initially planned (Stancliff et al., 2002). For clients who are prescribed
up to 250 mg comfortable weaning off the process can take a very long time.
An advantage of methadone maintenance is that it is safer to treat pregnant women.
When pregnant women have been using illicit opioids, it is safer to begin methadone
maintenance than it is to detox her. The fetus is likely not able to tolerate the physical withdrawal
symptoms that they will experience as a result of its inevitable addiction (Jones et al., 2007).
Methadone doses are brought up consistently to pregnant women whenever withdrawal
symptoms became apparent (Drozdick et al., 2002). By the end of the pregnancy, most women
are dosed in the 150–180 mg daily dose to avoid withdrawal for the baby (Drozdick et al., 2002).
Methadone maintenance can help those who have a serious opioid addiction to remain
safe if they are unable to stop using illicit opioids on their own for whatever reason. Higgins
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blindly dosed 39 participants with methadone maintenance beginning at 30 milligrams. Half of
the participants were given gradual reductions in their dose and half were not reduced, all
unknowingly (Higgins et al., 1986). The half who were maintained at the original dose remained
clean from opiates, determined by routine toxicity screens, but the group who had reductions all
had illicit substances in their toxicity screens (Higgins et al., 1986). This could imply that
methadone is a safer replacement, and therefore, is an effective deterrent to opioid abuse. In
Paulus and Halliday’s (1967) study, of one-hundred seventy-six patients were contacted after one
year, 43% reported that they felt more confident in their ability to remain sober following
treatment.
There have been some studies that have suggested that a client who is over the age of 30
with some type of familial support have a much higher chance of being successful on MMT
(Stimmel & Kreek, 2000). Seventy-two percent of a 370-patient study in this category were able
to maintain their sobriety past one year (Torrens et al., 1996). These clients were specifically
described as residing with family or a significant other and were also abstaining from alcohol
(Torrens et al., 1996).
A disadvantage of methadone maintenance is impaired driving. Some studies report that
methadone maintenance causes this (Bernard et al., 2009). They followed those who were
charged with driving violations who were found to have methadone on their blood (Bernard et
al., 2009). It was then ascertained if the subjects were on methadone maintenance or if they were
using street methadone (Bernard et al., 2009). These findings were collected between 2002 and
2006. Of the 635 drivers who were cited for driving under the influence, 502 were on methadone
maintenance (Bernard et al., 2009). This can indicate that many are receiving a dose of
methadone that is too great for their metabolism.
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Another disadvantage can be health issues. There are side effects of prolonged
methadone consumption. Some of these side effects include weight gain, headaches, nausea,
exhaustion, tooth decay, methadone poisoning (which causes death), brain damage, osteoporosis,
cognitive impairment, a continuation of drug dependency, reduction in heart functioning, organ
deterioration, and low oxygen levels which cause a blue tint to the lips and fingernails (Ball &
Ross, 2012; Benyamin et al., 2008; Kreek, 1973). Some of these effects can begin immediately,
and some occur over time (Benyamin et al., 2008). Methadone can impact heart function: It
prohibits the cardiac potassium channel HERG (a protein that helps to regulate heartbeat) and
can cause prolonged QT interval, meaning the heart takes too long to recharge in between beats
(Eap et al., 2007, 719–728). Three types of methadone are R-methadone, S-methadone, and RSmethadone. R-methadone appears to have a lesser effect on QT intervals (Eap et al., 2007, 719–
728).
If the client gets incarcerated while on methadone maintenance, in many states they are
not given their methadone doses, so they are forced to violently and painfully withdraw from the
synthetic opioid (Rich et al., 2015). Another drawback of MMT is that the clients are chained to
their location. They have to report to the clinic every morning for their dose. They are unable to
go on vacation or make plans that take up their whole day, or even go away overnight. Going to
the clinic daily can interfere with holidays, jobs, and can be a problem if the individual is sick.
There are cases when clients can be prescribed a small amount of take-home methadone or be set
up with guest dosing at another clinic, but this is not always granted as a client convenience.
Dental issues can be another drawback. Some types of methadone are made without sugar
to try to reduce the risk of tooth decay (Dasanayake et al., 2010). Methadone is a medication
that, even though most clinics use the sugar-free version, still promotes tooth decay in many
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cases (Nathwani & Gallagher, 2008). Clients who are on methadone long-term run the risk of
severe dental issues and tooth loss (Nathwani & Gallagher, 2008).
A drop in cognitive function can be another drawback to treatment. Prosser et al. (2006)
sought to find out whether cognition levels dropped during and after MMT. They studied 29
former heroin addicts who were currently receiving MMT, 27 who were done with MMT, and 29
who had no history of drug dependence (Prosser et al., 2006). Participants who were in long-term
MMT exhibited loss of cognitive functioning, while the loss of cognitive functioning of those
who were on MMT was less (Prosser et al., 2006). The third group not using MMT exhibited no
significant cognitive loss (Prosser et al., 2006).
Co-Occurring Disorders
Many who have opioid use disorder also have a mental health disorder. When this
happens, it is called a co-occurring disorder or comorbidity (Minkoff, 2001). It is estimated that
17.5 million, or 8% of the population in the United States, have co-occurring disorders (Ogloff et
al., 2015). Of this 8 only, 3% are estimated to receive treatment for both their SUD and their
mental health disorder (Watkins et al., 2001). Clients who have a co-occurring disorder would
face challenges, not only with having to overcome their substance use issues but dealing with
their mental health issues as well. It can be a cyclical problem, as they often use illicit substances
to address their mental health issues, which exacerbate their mental health issues, and the cycle
continues.
When a client has a mental health disorder, it is important to treat mental health issues if
the client is to remain clean and sober. Some ways to know if the client has a mental health
disorder while not diagnosing them amid their addiction is to delve into their history. Often, the
client has a history of psychiatric treatment and has received a diagnosis in the past, which can
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indicate the presence of a mental health issue (Sacks et al., 2013). If the client’s mental health
symptoms were present before their addiction, a mental health issue can be indicated. If the
client can recall experiencing specific symptoms in their childhood that are consistent with
current mental health symptoms that indicate a particular disorder, a mental health diagnosis may
be given (Swendsen et al., 2010).
There are many different diagnosable mental health disorders in the DSM 5. Some
appear to have a stronger connection to a substance use disorder than others (Swendsen et al.,
2010). Some of these disorders are major depressive disorder, generalized anxiety, panic
disorder, bipolar 1 and 2 disorder, attention deficit hyperactivity disorder, schizoaffective
disorder and schizophrenia, and post-traumatic stress disorder (PTSD) (Swendsen et al., 2010).
There are also a few personality disorders that appear to have a strong connection to SUDs
(Verheul, 2001). These include borderline personality disorder, antisocial personality disorder,
histrionic personality disorder, narcissistic personality disorder, paranoid personality disorder,
schizoid personality disorder, and schizotypal personality disorder (Verheul, 2001).
Major Depressive Disorder
Eighteen percent of clients who are diagnosed with major depression will have a history
of a co-occurring substance abuse problem (de Graaf et al., 2002). Symptoms of depression
include: depressed mood, diminished interest or pleasure, significant appetite or weight change,
insomnia, diminished ability to think/concentrate, irritability, lack of motivation, indecisiveness,
hypersomnia, psychomotor agitation, psychomotor retardation, social isolation, crying spells,
psychotic symptoms, fatigue or loss of energy, feelings of worthlessness, excessive guilt,
recurrent thoughts of death, decreased motivation, change in libido, feelings of hopelessness,
feelings of helplessness (APA, 2013).
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Generalized Anxiety Disorder
Fifty-nine percent of clients diagnosed with anxiety have a history of a co-occurring
substance abuse disorder (de Graaf et al., 2002). Symptoms of anxiety include excessive and
difficult to control anxiety and worry, restlessness, difficulty concentrating, or mind going blank,
irritability, muscle tension, sleep disturbance, easily fatigued (APA, 2013).
Panic Disorder
Twenty percent of those diagnosed with panic disorder will have a history of a cooccurring SUD (de Graaf et al., 2002). Symptoms of panic include sweating, palpitation,
pounding, accelerated heart rate, trembling or shaking, shortness of breath, feeling of choking,
chest pain or discomfort, nausea, feeling dizzy, unsteady, and lightheaded, feeling of
derealization, fear of losing control or going crazy, fear of dying, worry about consequences of
attacks, chills or hot flushes, numbing or tingling sensations, feelings of unreality or being
detached from oneself, persistent concern over additional attacks, maladaptive change in
behavior related to attacks (APA, 2013).
Bipolar 1 and 2 Disorder
Thirty to 50% of those diagnosed with bipolar disorder will have a history of a substance
abuse disorder (Substance Abuse and Mental Health Services Administration, 2016). Symptoms
of mania include elevated mood with abnormally increased activity/energy, irritable mood with
abnormally increased activity/energy, decreased need for sleep, talkative or pressured speech,
racing thoughts, flight of ideas, distractibility, increase in goal-directed activity, inflated selfesteem or grandiosity, psychomotor agitation, excessive pleasurable activities with painful
consequences, psychotic symptoms, depressed mood, diminished interest or pleasure, significant
appetite or weight change, insomnia, diminished ability to think/concentrate, irritability, lack of
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motivation, indecisiveness, hypersomnia, psychomotor agitation, psychomotor retardation, social
isolation, crying spells, psychotic symptoms, fatigue or loss of energy, feelings of worthlessness,
excessive guilt, recurrent thoughts of death, decreased motivation, change in libido, feelings of
hopelessness, and feelings of helplessness (APA, 2013).

Schizoaffective Disorder
As many as half of clients who are diagnosed with schizoaffective disorder will be
diagnosed with a co-occurring SUD (Dixon et al., 1991). Symptoms of schizoaffective disorder
include delusions, hallucinations, disorganized speech, grossly disorganized behavior, catatonic,
loss of interest, loss of pleasure, poverty of speech, poverty of thought, flattened affect, poor
hygiene, social isolation with the following concurrent symptoms of an episode of a major mood
disorder: depressed mood, diminished interest or pleasure, significant weight change, insomnia,
hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, diminished ability
to think or concentrate, indecisiveness, recurrent thoughts of death, feelings of worthlessness or
excessive guilt, inflated self-esteem or grandiosity, decreased need for sleep, talkative or
pressured speech, flight of ideas or racing thoughts, distractibility, increased goal-directed
activity or psychomotor agitation, and excessive pleasurable activities with painful consequences
(APA, 2013).
Schizophrenia
As many as half of those diagnosed with schizophrenia will have a history of a substance
abuse disorder (Dixon et al., 1991). Symptoms of Schizophrenia include delusions,
hallucinations, disorganized speech, grossly disorganized behavior, catatonic, loss of interest,
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loss of pleasure, poverty of speech, poverty of thought, flattened affect, poor hygiene, social
isolation (APA, 2013).
Attention Deficit Hyperactivity Disorder (ADHD)
Twenty-five percent of those diagnosed with SUD will also be diagnosed with ADHD
(Slobodin, & Crunelle, 2019). Symptoms of ADHD include inattention to details, careless
mistakes in work, difficulty sustaining attention in tasks or play, does not seem to listen,
difficulty organizing tasks, avoids tasks requiring sustained mental effort, does not follow
through on instructions, and fails to finish tasks, loses things necessary to tasks, easily distracted
by extraneous stimuli, forgetful in daily activities, fidgets or squirms, leaves seat in classroom,
runs about or climbs excessively when not appropriate, difficulty playing quietly, on the go, talks
excessively, blurts out answers, difficulty waiting for turn, and interrupts or intrudes on others
(APA, 2013).
Post-Traumatic Stress Disorder (PTSD)
Those who are diagnosed with PTSD are two to four times more likely to be diagnosed
with a co-occurring SUD than those who are not diagnosed with PTSD (McCauley et al., 2012).
Symptoms of PTSD include exposure to actual or threatened death, serious injury, or sexual
violence in one or more of the following ways: directly experienced traumatic event, personally
witnessed the event(s) occurring to others, learning a traumatic event occurred to close family or
friend, repeated or extreme exposure to aversive details of traumatic event intrusive distressing
recollections, repetitive play with traumatic themes expressed, distressing dreams related to
traumatic event, frightening dreams may have not recognizable content, acts or feels as if event
were recurring, trauma specific reenactment may occur in play, intense distress at exposure to
cues, physiological reactivity to cues, difficulty falling asleep, difficulty staying asleep,
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irritability and angry outbursts, difficulty concentrating, hypervigilance, exaggerated startle
response, reckless or self-destructive behavior, avoids activities, places and people that remind of
event, inability to remember aspects of traumatic event, persistent exaggerated negative beliefs
about self, persistent distortions about cause of event leading to self-blame, persistent negative
emotional state (fear, horror, anger, etc), diminished interest or participation in activities,
detachment or estrangement from others, and inability to experience positive emotion (APA,
2013).
Personality Disorders
Personality disorders are characterized by a pervasive pattern of behaviors and
maladaptive ways of relating to others and reacting to social cues (Shedler et al., 2010). These
factors are maladaptive to the point of impeding life functioning and interpersonal functioning
(Shedler et al., 2010). These disorders are thought to be caused by genetic and/or environmental
factors (Shedler et al., 2010). Symptoms can be managed or alleviated over time with proper
treatment, and insight on behalf of the client (Bateman et al., 2015). Treatments normally include
psychotherapies and group therapies (Bateman et al., 2015) Personality disorders are grouped
into clusters (Bateman et al., 2015). Cluster A includes disorders characterized as odd or
eccentric (Bateman et al., 2015). Cluster B includes disorders characterized by extreme
emotionality or erratic behavior (Bateman et al., 2015). Cluster C is characterized by appearing
anxious or fearful (Bateman et al., 2015).
All personality disorder diagnosis requires the following: persistent maladaptive
characteristics with two or more of the following: maladaptive cognition, affectivity,
interpersonal functioning, and impulse control; significant distress or impaired functioning, and
early onset adolescence or early adulthood (Zimmerman, 1994). Nine and one-third of the
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population suffer from a personality disorder (Verheul, 2001). Some personality disorders are
more commonly associated with SUDs.
Antisocial Personality Disorder
A very high rate of those who are diagnosed with an antisocial personality disorder will
have a co-occurring SUD with an estimated percentage rate of co-occurrence at over 23% (Trull
et al., 2010). Antisocial personality disorder is characterized by social irresponsibility, disregard
for others’ feelings or well-being, deceitfulness, and manipulative behaviors (APA, 2013). This
personality disorder is usually revealed in the teenage years and follows the individual into the
individual’s adulthood (Myers et al., 1998).
Borderline Personality Disorder
Borderline personality disorder is highly comorbid with diagnosed SUDs, with an
estimated percentage rate of 58.7% (Trull et al., 2010) (Sansone & Sansone, 2011). BPD
symptoms include frantic efforts to avoid real or imagined abandonment, pattern of unstable or
intense relationships, unstable self-image, and impulsivity in at least two potentially damaging
areas (APA, 2013). It also includes recurrent suicidal or self-mutilating behaviors, affective
instability and excessively reactive mood, chronic feelings of emptiness, transient and stressrelated paranoia, and severe dissociative symptoms (APA, 2013).
Schizoid Personality Disorder
Just over 11% of those diagnosed with schizoid personality disorder will be dually
diagnosed with a substance abuse disorder (Trull et al., 2010). This personality disorder is
characterized by a lack of desire in close relationships with others, organizing one’s life to avoid
having to interact with other people, and preferring to be alone (APA, 2013). It might also
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include enjoying few activities, not desiring sex, inability to relate to others, feeling indifferent to
criticism or compliments, acting aloof, and showing little emotion (APA, 2013).
Schizotypal Personality Disorder
Over 16% of those who have schizotypal personality disorder also have been diagnosed
with a substance use disorder (Trull et al., 2010). Schizotypal personality disorder is
characterized by strange thinking patterns, odd behaviors, lack of emotion, absence of emotional
responses to cues, odd speech, rambling speech, lack of close friends, socially anxious, and
paranoid thinking (APA, 2013). The odds of an individual being diagnosed with schizoid
personality disorder are between one and two percent (Trull et al., 2010).
Dependent Personality Disorder
Approximately 27.34% of those diagnosed with dependent personality disorder will also
be diagnosed with a substance abuse problem (Trull et al., 2010). Dependent personality disorder
is characterized by an inability to be independent. The individual depends on another person to
fulfill all of his or her needs. Those with dependent personality disorder will have difficulty
making everyday decisions without excessive reassurance from others, a need for others to
assume responsibility for all major areas of his or her life, difficulty expressing disagreement for
fear of not being liked, going to excessive lengths to obtain support, feeling of fear when alone
due to the feeling that they cannot care for self, and seeking a new relationship desperately when
a relationship ends (APA, 2013).
Paranoid personality disorder
Over 13% of those who have been diagnosed with paranoid personality disorder will also
be diagnosed with a substance use disorder (Trull et al., 2010). This disorder is characterized by
feeling as though others are out to get the individual for no apparent reason, and hypersensitive
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to criticism (APA, 2013). The client might also be angry and hostile, short-tempered,
argumentative, defensive, may appear to be eccentric, distrusting of others, even family members
(APA, 2013).
Narcissistic personality disorder
Almost 12% of those diagnosed with narcissistic personality disorder will also be
diagnosed with a substance use disorder (Trull et al., 2010). This disorder is characterized by
emotional dysregulation, fragile self-esteem, and grandiosity (APA, 2013). These individuals
might also have an inflated sense of importance, lack of empathy, need admiration from others,
and have troubled relationships (APA, 2013).
Histrionic Personality Disorder
Almost 18% of those diagnosed with histrionic personality disorder will also have a cooccurring substance abuse disorder (Trull et al., 2010). This disorder is characterized by dramatic
and attention-seeking behaviors (APA, 2013). Those who are histrionic need to be noticed and be
dramatic or inappropriate things to get attention. They might have a distorted self-image and
might manipulate to gain approval (APA, 2013).
It can be difficult when diagnosing a client to know if a substance abuse problem is
causing the mental health issue, or if it is a symptom of a mental health issue (Minkoff, 2001).
For this reason, it is always best practice to not diagnose a client with a mental illness until they
have been clean and sober for a minimum of six months (APA, 2013). This can prove to be
difficult because the client, if they are self-medicating, will likely have difficulty maintaining
sobriety for six months if they are not medicated for their mental health. It is a difficulty that
causes many individuals to become caught in the cycle of addiction.
Treatment for Those with Co-Occurring Disorders
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Some who suffer from substance addiction also have a mental health diagnosis.
Co-occurring disorder is a term for those who suffer from substance addiction and a mental
health disorder. Some may require treatment with psychotropic medications to treat their mental
health issues to remain sober, or else they may continue to self-medicate with illicit substances
(Oldani, 2014). For those with a co-occurring disorder, the initial treatment can be very similar
depending on the severity and nature of their mental health condition (Hegel, 1932).
If the client is already being treated for mental health issues and has an outpatient
prescriber, their initial treatment is mostly the same as those without a co-occurring disorder
(Drake et al., 2004). They need to be detoxed from the illicit substance while still being
administered their mental health medication (Beaini et al., 2000). Clients who are not being
treated for their mental health issues need what is called dual diagnosis treatment (McGinty et
al., 2015). Dual diagnosis inpatient treatment consists of the client receiving medical
detoxification from the addictive substance, while receiving mental health counseling and
medication management from a psychiatric prescriber (Drake et al., 2004). Evidence has shown
that co-occurring disorder should be treated simultaneously and that treating substance addiction
only puts the client at risk for relapse (McKee, 2017). Despite this, accurate diagnosis of mental
health disorders cannot take place until the client has been clean and sober for a minimum of six
months unless they have been previously diagnosed. Substance abuse and withdrawal symptoms
can induce depression and anxiety (Quello et al., 2005). These factors make accurate diagnosing
and treatment complex for those with a co-occurring disorder (Quello et al., 2005). For these
reasons, the client needs to maintain follow up treatment to assess their medication needs. Some
clients may not need to treat mental health symptoms after their substance abuse issues are under
control, and some may need to continue treating their mental health symptoms in order to remain
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sober. Following this treatment, the client will follow the same treatment plan as a client who has
a substance use disorder, but with the help of medication management and individual therapy by
an outpatient therapist and a psychiatrist (Corrigan et al., 2009).
Many do not wish to address their mental health issues, either due to denial that they have
an issue, embarrassment, or lack of motivation, as this type of treatment requires much follow up
and consistency (Rohsenow et al., 2004). Those with a substance use disorder normally focus on
the daily habit of obtaining and using substances. Therefore, consistency with many of the
responsibilities of follow-up care is often not a priority (Andersson, Wenaas, & Nordfjærn,
2019). They might also be reluctant to seek mental health treatment due to the stigma placed
upon those with a mental health disorder (Rohsenow et al., 2004). This is a portion of the reason
why many begin using substances initially. It can be difficult to admit there is an emotional issue
that needs treatment, so many self-medicate and become addicted before they can realize that it
is happening (Barry et al., 2014).
Those with co-occurring disorders will need additional treatment along with substance
abused treatment (Horsfall et al., 2009). If clients only treat the substance abuse issue and not the
mental health problems, it is more likely that they will relapse. For the client to become truly
healthy a well-rounded approach must be taken (Horsfall et al., 2009). This study will seek to
study the effectiveness of MMT for those with and without co-occurring disorders to assess how
effective MMT is for those with a substance abuse problem only, and for those with a cooccurring disorder.
Summary
There are different reasons that people become substance abusers. Some appear to be
genetic and some appear to be environmental (Swendsen et al., 2009). There are times when the
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issue appears to be connected to childhood or adulthood trauma which can change the brain
synapsis makeup (Friedman et al., 1993). Sometimes it seems that there is no precursor at all,
but this is not usually the case. It appears that substance addiction is often co-occurring with
mental health disorders (Garland, Pettus-Davis, & Howard, 2013). This seems to imply that one
causes the other; therefore, both need to be treated for the client to obtain a healthy mind and
body.
Neurochemical addiction happens when the individual develops a dependence on a
substance (Herz & Shippenberg, 2012). The pleasure pathways are activated, and the client finds
it increasingly difficult to resist the urge to use the substance (Herz & Shippenberg, 2012). The
client gets physically ill if they do not consistently have the substance as the body now expects it.
This can happen with opioids, benzodiazepines, and alcohol.
Physiologically, the allure of using illicit substances is the way that it makes the user feel.
Euphoria is a common effect, as is an increase in dopamine and serotonin (Herz & Shippenberg,
2012). Opiates numb emotions and cause the user to experience a “high” feeling when used in
excess. Physical pain is also negated with opioid use (Bond et al., 1998). Physical addiction
comes quickly with regular opiate use (Herz & Shippenberg, 2012).
Theories of why individuals become addicted to substances vary. Sometimes there are
numerous reasons for one’s addiction issues. One theory is social learning theory which indicates
such things as growing up around substance users in the family or in the neighborhood (Akers et
al., 1989). This theory can also have to do with the individual’s peers and what they choose to
spend their time doing (Peralta & Steele, 2010). Observing addictive behaviors can elicit the
same behaviors in the individual.
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Another theory of addiction is that it is genetic. This theory deduces that addiction is a
genetic disorder that is passed down from generation to generation and predisposes individuals to
addictive tendencies (NIDA, 2019). Exposure theory indicates that individuals who are
unwittingly exposed to illicit substances become physically addicted due to being exposed
(jointcomission.org). This theory implies that individuals such as substance-exposed newborns
are much more likely to become addicted to substances later in life.
Social control theory suggests that there is an array of outside influences that affect an
individual’s chances of success in obtaining and maintaining sobriety (NIDA, 2019). Some of
these influences include family, friends, employment, and education. This theory contends that
those who have strong outside supports and protective factors have a greater chance of success
(NIDA, 2019).
Harm reduction theory contends that assisting substance users to use in a safe
environment while not forcing them to stop their behaviors reduces illness and death by overdose
and disease (Wermeling, 2010). Clients might be given clean needles or bleaching kits for their
needles. Clients might also be given medications that satiate their opioid addiction but are
administered daily by professionals who monitor the clients closely for safety and compliance.
There are many options for addiction treatment. Some of these include medicated
treatments like Suboxone, methadone, and Vivitrol (Bell & Strang, 2020). Some treatments are
not medication-related, like therapy and group attendance (Furst, 2013). Many clients who have
a substance addiction problem also have a mental health issue (Minkoff, 2001). For substance
use treatment to be effective for someone with comorbidity their mental health issues must be
treated (Sacks et al., 2013). This usually consists of individual therapy and possibly medication
management. Some other types of non-medicated treatment usually employed with substance
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abusers include CBT, motivational interviewing, relapse prevention, and contingency
management (Jhanjee, 2014). Other treatment modalities include therapeutic communities,
residential treatment, and support groups, including Alcoholics Anonymous and Narcotics
Anonymous (Jhanjee, 2014).
It can be difficult to determine if a substance use disorder is caused by a mental health
disorder or if the opposite is true (Minkoff, 2001). Those with a co-occurring disorder require a
more diversified treatment approach that addresses SUD along with the mental health issue
(Watkins et al., 2001). If one is treated without the other the chances of success are not as
promising.
After much investigation, the research appears to show a lack of information on how
MMT impacts non-recidivism in treatment. When an individual with an addiction problem
chooses to obtain MMT as their treatment method, it is unknown if this method truly affects the
client’s long-term sobriety, or if the client has a high likelihood of relapse, compared to other
forms of treatment. This also appears to be the case for non-methadone treatments. While studies
have been completed on the effectiveness of treatments in stopping illicit substance use, they
normally do not follow through with the client to assess their quality of life and ability to remain
sober.
When researching MMT many consistencies emerge. Some of these consistencies are that
MMT has shown to reduce harm from those who had risky opioid use behaviors, such as needle
sharing and selling sex for substances. The focus of most research has been on getting clients off
the street and away from risky behaviors initially. Monitored MMT doses also ensure that there
is no danger of overdose if the client does not continue to use illicitly in addition to MMT.
Another consistency is that MMT allows treatment providers to monitor clients closely and
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consistently. For clients with co-occurring disorders, their mental health treatment can be
monitored as well as their mental status. It can also keep the clients accountable for their mental
health treatment regimen.
What the research on MMT has not shown is how effective it is to help the clients obtain
their sobriety long term. It also has not shown if it is more effective than other kinds of
outpatient substance use treatment. Research has also not shown if MMT treatment is any
difference in effectiveness for clients with a co-occurring disorder as opposed to those without.
The research has grouped all the clients and has not considered that there might be a difference
in effectiveness between those with a co-occurring disorder and those without.
It has not been shown if MMT is the best treatment choice for those with co-occurring
disorders, if they are more likely to be consistent with treatment, or if they are more likely to
maintain their sobriety long term, or if another treatment is more effective. Most studies also do
not show the rate of recidivism in treatment within one year. The research shows that there is a
good rate of clients stopping the illicit use initially, but if the client relapses and is in and out of
treatment repeatedly, showing an ineffectiveness in the treatment, has not been shown. This is
true for those with and without co-occurring disorders.
The reason this writer chose to compare methadone treatment to all other treatments is
due to the sheer number of clients that are treated with methadone maintenance as opposed to
other forms of treatment. It must be determined if this is the best treatment method for clients to
get better permanently. This is a neglected area of study, especially for those with co-occurring
disorders. This writer chose to approach this research based on Maslow’s hierarchy of needs.
This is because the purpose of any type of treatment is to help the clients to obtain their basic
needs so they can live a happy life. As the clients are stable in their basic needs, they can move
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onto less basic needs and accomplish becoming productive members of society and fulfilled
human beings.
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CHAPTER THREE: METHOD
Overview
This research involved archival data analysis using data collected from a mental health
and addiction treatment center in Massachusetts to determine under what conditions outpatient
opioid addiction treatment are most effective. Information collected pertains to the client’s
diagnosis, treatment modality, length of time in treatment, gender, race/ethnicity, age, and reason
for discharge from treatment. This facility provides treatment services including MMT,
Suboxone treatment, Vivitrol treatment, individual counseling, psychiatry, psychoeducational
groups, intensive outpatient, inpatient detoxification, inpatient dual diagnosis services, and health
care services, all directed toward those with substance abuse issues and co-occurring disorders.
This data was used to determine under which circumstances different treatment modalities
provide better than expected treatment outcomes. Having a large data source from which to draw
can impact treatment by analyzing patterns in the effectiveness of different kinds of treatment
modalities. This can help providers to adjust treatments to more effective methods to help clients
to achieve long-term sobriety. The detailed data collection and analysis process is described in
this chapter.
Design
Statistical analysis allows researchers to predict future outcomes of a large population by
analyzing a sample of data from a smaller population (Johnson & Wichern, 2002). This is
important in making decisions about future treatment methods. For this study, a quantitative,
categorical research design using archival data was utilized. A type of analysis called a
classification tree analysis, or decision tree analysis, was used to determine whether the desired
target is being reached. A classification tree can help to depict how variables can affect an
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outcome (Song & Ying, 2015). In this study, the tree would allow analysis of how different
addiction and mental health treatments affect client success in staying clean from opioids long
term. This type of analysis is often used for program evaluation (Taxman & Kitsantas, 2009).
This use is consistent with this study due to all the data coming from a sole treatment facility.
These types of studies have been completed in similar programs such as jails and in public health
settings. Stalans et al. (2004) analyzed recidivism in incarceration with violent offenders who
were on probation following release from prison. They used the classification tree analysis model
to depict variables that affected the prisoners’ outcomes. Lemon et al. (2003) analyzed the
effectiveness of classification tree analysis in public health programs and programs servicing atrisk populations. They concluded that CTA was able to efficiently classify the population into
“meaningful subgroups” (Lemon et al., 2003). It found that CTA was a helpful research tool
(Lemon et al., 2003). They also cited examples of CTA studies used in the public health center
assessing the effectiveness of treatments for those who received caesarian sections, influenza
treatment, and treatment for obesity (Lemon et al., 2003).
A categorical study is appropriate because this study examines the characteristics of each
category that contribute to success in sobriety. This is one way to conduct research when there is
no experiment happening (archival data sets). It is used to ascertain the conditions under which
certain treatments are most successful by comparing the expected success rate to the actual
success rate. This type of study allows for no manipulation of treatment factors. It is often used
in studies that include psychological factors (Thompson, 2010).
Treatment success was measured in the completion of treatment. Completion of treatment
was defined as those who remain in treatment without relapse for 1 year following initially
obtaining sobriety and enrolling in treatment or those who were weaned off treatment properly in

63
accordance with their treatment plan. Unsuccessful treatment was measured by those who
relapsed, died, or left treatment due to other factors, such as administrative discharge (being
removed from the program), having positive urine drug screens, or incarceration.
Research Questions
The overarching research question is: Under what conditions are outpatient opioid addiction
treatment most successful?
RQ1: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with MMT?
RQ2: Is there a statistically significant difference between expected and actual success rate in
those with opioid use disorder when treated with Suboxone?
RQ3: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with Vivitrol?
RQ4: Is there a statistically significant difference between the expected and actual success rates
in those with opioid use disorder when treated with individual counseling?
RQ5: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with group counseling?
RQ6: Is there a statistically significant difference between the expected and actual success rates
in those with opioid use disorder when treated with IOP?
RQ7: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with psychiatry?
RQ8: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with family intervention?
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Hypothesis
H01: There will not be a statistically significant difference between the average (overall sample)
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with MMT.
H02: There will not be a statistically significant difference between the average overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with Suboxone.
H03: There will not be a statistically significant difference between the average overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with Vivitrol.
H04: There will not be a statistically significant difference between the expected overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with individual counseling.
H05: There will not be a statistically significant difference between the expected overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with group counseling.
H06: There will not be a statistically significant difference between the average sample success
rate and actual success rates in those with opioid use disorder or a co-occurring disorder when
treated with IOP.
H07: There will be a statistically significant difference between expected and actual success rates
(long-term sobriety) in those with opioid use disorders when treated with psychiatry.
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H08: There will be a statistically significant difference between expected and actual success rates
(long-term sobriety) in those with opioid use disorders and co-occurring disorders when treated
with family intervention.
Participants
The location of the treatment facility, providing the data of this study, is in a city that is
characterized by blue-collar workers, high rates of lower-income families, and higher than
normal rates of individuals who abuse heroin. According to facility records the clients serviced at
this facility are primarily from Massachusetts and Rhode Island. The clientele of this facility
range in age from 18 to 80, with most being between the ages of 22–45, according to the records.
The area where the data was collected has suffered many deaths due to the opioid epidemic. In
2016 65 people died from opioids overdosed in this area (Centers for Disease Control and
Prevention [CDC], 2017). This is triple the amount that of deaths due to opioid overdose in 2012
(CDC, 2017). As the city’s populace is approximately 88,000 residents, this means that one out
of every 1,354 died from an opioid overdose, which is more than five people per month.
The participants of this study were opioid users randomly drawn from a convenience
sample of archival data, gathered from the treatment facility, by a computer-generated draw. The
data was drawn from clients who began treatment in, or prior to, July 2016, and were followed
until a year from the beginning of individual treatment episodes. Unsuccessful clients are those
who have dropped out of treatment prior to one year, without transferring to another program or
completing a medication taper consistent with their treatment plan. Successful treatment includes
clients who have remained in treatment for one year without relapsing, those who have
transferred to another treatment program, or those who have tapered off their medication in
compliance with their treatment plan. The data gathered included treatment modality, age,
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race/ethnicity, gender, diagnoses (SUD and co-occurring), length of time in treatment, and
reasons for discharge from treatment, when available.
Clients who presented were assessed by an extensive intake evaluation at the treatment
facility and were determined to have opioid use disorder or a -co-occurring disorder. All the
archival information for this study was collected by master’s level clinicians who have been
trained to assess and give diagnostic impressions of each client. They have also been trained to
recommend treatment options based on the desires and needs of individual clients.
All participants remained confidential, and the data collected was archival data that had
been reported from this treatment facility to the BSAS. The clients were a mix of race, age, and
gender. Many were homeless and unemployed with limited social supports. Many were involved
in risky behaviors such as crime and promiscuity.
Treatment Choice
When the assessment is complete, recommendations are either confirmed from the
original triage clinician or, depending on the detailed information obtained, the recommendation
could be changed by the evaluating clinician. Ultimately, the treatment option is chosen by the
client and the clinician together. The client is not forced into any type of treatment, however, if
the clinician does not feel that the client is appropriate for their preferred treatment, they are not
offered that option for treatment.
Criteria for treatment depends on the specific treatment options. If a client wishes to
pursue MMT they have had an opiate addiction for a minimum of six months. Clients do not
have to be actively using opiates, but those in full remission do not qualify. The same
requirements apply for Suboxone treatment, except that the client must not have any opiates in
their system at the time of the first dose of Suboxone. This means that the client cannot have
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used any opiates for three days prior to their first dose. For clients seeking Vivitrol, they must be
opiate free for 10 days prior to receiving the injection. For this reason, many clients go into
inpatient detox and receive their first injection before leaving treatment. For a client to qualify
for all other outpatient treatments, including counseling, intensive outpatient, and group therapy,
the client does not have to be clean and sober; however, they cannot show up to treatment while
under the influence or they will be asked to leave for the day. The reason for this is that they are
a barrier to other clients in this condition, and they cannot gain anything from treatment if they
are not lucid.
The client data is saved in the facility’s computer system through their data analytics
department, and it is also reported to BSAS. This data is used to attempt to improve treatment
and increase the effectiveness in assisting clients in obtaining and maintaining sobriety. The data
analytics department has access to programs that can run statistics to answer many questions that
might be addressed. For example, questions can be answered such as how many clients who
were referred to inpatient treatment completed their treatment episode in January 2017. This
helps to improve treatment practices and to explore new treatment methods.
Sample Size
For this study, the sample studied was 1,000 clients. G*Power (G*power for MAC
version 3.1.9.3) was used to determine the appropriateness of this sample size. This program
determined that the minimum sample size would be 73 participants when the effect size is 50%,
the margin of error is 5%, and the statistical power is 95%. Therefore, the sample size that would
be used was more than adequate.
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F tests - MANOVA: Repeated measures. within- between interaction
Number of groups = 2 . Number of measurements = 4.

err prob = 0 .0 5 . Effect size f(V) = 0 .5
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Total sample size

60
50

Effect size f(V)

40

= 0.5

30
20
10
0
0.6

0.65

0.7

0.75

0.8

0.85

0.9

0.95

Power (1-β err prob)

critical F = 2.7375
0.7
0.6
0.5
0.4
0.3
0.2
0.1

α

β

0
2

4

6

8

10

12

14

16

18

Note. Reprinted from G*Power, retrieved from https://www.g-power.com/ Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A.
(2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior
Research Methods, 39, 175

69

Procedure
Sample Data Collection
The quality analytics department of the treatment center has access to over 5,000 records
of clients presenting for treatment. This department retrieved only information from clients who
have been diagnosed with opioid use disorder or opioid use disorder and a co-occurring mental
illness. The information drawn included type of treatment, age, race, gender, diagnosis, length of
time in treatment, and reasons for discharge from treatment when available on 5,000 randomly
chosen records. This writer then stripped the records of names manually in front of the outpatient
director of the treatment facility, shredded the names, assigned each client a number, and sorted
the numbers using the app Random Num for the Apple iPhone, which chose 1,000 random
numbers. This ensured that the sample is randomly drawn.
Data Entry
Once obtained from the treatment facility, each record was manually entered into SPSS.
For each participant, the information to be retrieved and recorded includes gender, racial/ethnic
background, diagnosis, treatment modality, and whether treatment was successful, defined as
remaining in treatment for 1 year without relapsing. Each of the 1,000 records was manually
entered into SPSS according to the following codes:
•

Gender (M male; F female)

•

Racial/ethnic background (CA Caucasian; AA African American; HA Hispanic; AS
Asian; EE eastern European; NA other)

•

Diagnosis (OP opioid use disorder alone; CO co-occurring opioid use disorder and a
mental health disorder)
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•

Treatment (MMT; BUP for Buprenorphine, Suboxone, Sublocaid, Zubsolv, Bunavil; IOP
intensive outpatient; THE therapy, PSY psychiatry; VIV Vivitrol)

•

Treatment success (Y yes; N no)
Data Analysis

Determining Success Rate of the Sample
CHAID is a decision tree model that stands for chi-square automatic interaction
detection. This model performed the chi-square test many times to choose the predictors that
produce outcomes that are the closest to the projected target outcomes (Milanović &
Stamenković, 2016). CHAID was used to calculate the overall success rate of the sample. This
rate was used as a point of comparison for each category. Comparing the number of people who
remain in, and complete treatment, instead of relapsing, between MMT and other modalities of
substance abuse treatment, allows an understanding of the effectiveness of each type of treatment
for long-term sobriety.
The chi-square test split the branches, or nodes, of the category tree until there is no
statistically significant difference between the nodes. Each cell of the tree represented a unique
combination of variables. Then, each cell’s success rate was compared to the overall
population’s success rate. This helps to predict which treatments have better than expected
success rates from the categories of treatments studied (Milanović & Stamenković, 2016).
Determining the Success Rate of Each Cell
In classification tree analysis, records branch off at each cut point. For example, one cut
point might be gender. Each of these “male” and “female” branched further branches off at
additional cut points. Each record was eventually assigned to a cell determined by unique
characteristics. For example, one cell might consist of male African American clients with opioid
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use disorder alone who were treated with MMT only. As an example, if 20 records are assigned
to this cell, and ten of these records indicate successful treatment, then the success rate of this
cell is 50%. This figure is then compared to the success rate of the entire sample, and SPSS
determines whether a difference in success rate of any individual cell is statistically significant.
Comparing the number of people who remain in, and complete treatment, instead of relapsing,
between MMT and other modalities of substance abuse treatment, offers an understanding of the
effectiveness of each type of treatment for long-term sobriety.
Summary
Information concerning the client’s diagnosis selected treatment modality, and other
factors was collected from a drug treatment facility in Massachusetts. This information was
analyzed using a category tree analysis in SPSS to determine under what conditions are
treatments the most effective. This analysis could help to give treatment providers useful
information pertaining to the increasing effectiveness of treatments for opioid users.
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CHAPTER FOUR: FINDINGS
Overview
The purpose of this study is to assess which treatments for opioid use disorder patients
have had the most success and what factors contributed to the success. The data that was utilized
for this study was archival data from 2016 to 2018 of 1,000 patients randomly drawn from a pool
of 5,000 records from a substance use treatment facility in Massachusetts. The data collected by
this writer was analyzed through the statistical analysis software SPSS. This writer entered all
the collected data into SPSS and used the information to complete a category tree analysis using
CHAID. This presented a category tree that provided a visual representation of the factors that
most influenced the client’s longevity in treatment. Longevity in treatment is important in
determining which treatments are effective because the brain takes time to heal from opioid
addiction and must be given time (Brick, 2012). If clients are dropping out of treatment early, it
can be assumed that they are not recovered and have a high probability of not abstaining from
illicit substances. This chapter provides specific measures and information to support the
findings of this study.
This chapter begins with the descriptive information included in the CTA. This includes
demographic information for the participants and length of time in treatment for all treatment
categories. Next, the results of the CTA are thoroughly explained with each of the research
questions and hypotheses addressed. Finally, the implications of the results are discussed as well
as the limitations of the study and suggestions for further research. The conclusion ends the
chapter and wraps up all the findings of the CTA.
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Descriptive Statistics
It was originally planned that the definition of successful treatment would be defined as
any client who had been in treatment for 12 months or more, however, after collecting the data it
was discovered that not enough of the sample population had achieved this length of time in
treatment. Therefore, the definition of success was revised to be defined as six months or more in
treatment. Other studies have defined a successful treatment episode as 6 months length of time
(Grall-Bronnec et al., 2019). Since successful treatment is defined as 6 months or more in
treatment, there were 543 successful clients.
Table 1
Length of Time in Treatment
Time period
Less than 3 months
3-6 months
6-9 months
9-12 months
more than 12 months
total

Number
273
184
198
153
192
1,000

Percent
27.3
18.4
19.8
15.3
19.2
100

Of the 1,000 participants included in the sample 27.3% (n=273) remained in treatment for
less than 3 months. Of the overall sample 18.4% (n=184) remained in treatment for 3–6 months,
19.8% (n= 198) who were in treatment for 6–9 months, and 15.3% (n= 153) for 9–12 months.
The clients who remained in treatment for 12 or more months accounted for 19.2% (n=192).
Table 2
Gender
Gender
male
female
Identified transgender
total

Number
362
179
2
543

Percent
66.7
33
.3
100
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Of the 1,000-participant sample, 543 were successful. The sample included two people
who identified themselves as transgender (.3%), 66.7% men (n=362) and 33% women (n=179).
Thus, the majority of the successful population was male.
Table 3
Ethnicity
Ethnicity
Caucasian
African American
Hispanic
Asian
European
Unknown
total

Number
412
77
17
3
27
7
543

Percent
75.9
14.2
3.1
.55
5
1.2
100

Caucasians accounted for most of the successful portion of the sample with 75.9%
(n=412). The rest of the successful portion of the sample consisted of African Americans 14.2%
(n=77); 3.1% Hispanics (n=17); 0.55% ; Asians (n=3); 5% Europeans (n=27); and 1.2%
unknown (n=7).
Table 4
Employment
Employment
employed
unemployed
unknown
total

Number
115
406
22
543

Percent
21.2
75
4.1
100

Of the 546 successful participants in the sample, 21.2% were employed (115). There
were 75% (n=406) who were unemployed. The last 4.1% (n=22) employment status was
unknown.
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Table 5
Housing
Status
Not homeless
homeless
unknown
total

Number
441
92
10
543

Percent
81.2
16.9
1.8
100

Of the 543, 81.2% (n=441) were not homeless and 16.9% (n=92) were homeless. There
were 1.8% (n=10) whose housing status was unknown. The unknown portion of the sample
could be due to frequent changes in housing status.
Treatments
The original proposal identified treatment categories of methadone maintenance,
Suboxone, Vivitrol, psychiatry, individual counseling, group counseling, family intervention,
and IOP, but as this data was being analyzed it was determined that there were additional
categories that should be added for those who were involved in multiple treatments in
conjunction with each other. These situations represented a large portion of the data. Additional
categories that were analyzed include methadone and counseling; methadone with counseling
and psychiatry; Vivitrol and counseling; Vivitrol with counseling and psychiatry; Suboxone and
counseling; Suboxone with counseling and psychiatry; group counseling and individual
counseling; and psychiatry with counseling. It was also determined that there was no way to
access information concerning family intervention from the data provided. Therefore, this
category was eliminated. The category of psychiatry alone as a treatment was also omitted due to
there being no participants in this category.
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Table 6
Treatment Modality
Modality
Methadone
Suboxone
Individual
counseling
Group counseling
IOP
Vivitrol
Suboxone and
counseling
Suboxone,
psychiatry, and
counseling
Methadone and
counseling
Methadone,
psychiatry, and
counseling
Individual and
group counseling
Vivitrol, psychiatry,
and counseling
Vivitrol and
counseling
Psychiatry and
counseling
Total

Number Number Number TOTAL percent
6-9 mo. 9-12
>12 mo.
mo.
23
19
33
75
13.8
11
7
10
28
5.2
13
10
6
29
5.3
11
1
3
19

6
0
3
7

4
1
4
11

21
2
10
37

3.8
.37
1.8
6.9

9

7

6

22

4

23

26

39

88

16.2

28

13

27

68

12.5

15

19

8

69

12.7

11

6

4

32

5.8

2

4

1

12

.18

29

19

38

144

26.5

198

153

192

543

100

Of the successful portion of the sample, being defined as 6 months or more in treatment,
13.8% (n=75) people were being treated with methadone. There were 5.2% (n=28) participants
in Suboxone treatment, and 5.3% (n=29) participants in individual counseling. Group counseling
accounted for 3.9% (n=21), while .4% (n=2) utilized intensive outpatient (IOP). There were
1.8% (n=10) in Vivitrol treatment. Suboxone and counseling accounted for 8.1% (n=44) of the
sample, while 4.1% (n=22) who engaged in psychiatry, counseling, and Suboxone treatment
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simultaneously. There were 16.2% (n=88) participants in methadone and counseling treatment
simultaneously. Psychiatry, counseling, and methadone simultaneously accounted for 10.6%
(n=58) of the sample. There were 7.7% (n=42) participants in individual counseling and groups
simultaneously. There were 3.9% (n=21) participants in psychiatry, counseling, and Vivitrol
simultaneously. Seven participants (1.3%) who were in Vivitrol and counseling simultaneously,
and 15.8% (n=86) participants in psychiatry and counseling simultaneously.
Of the total sample, 198 participants remained in treatment for 6–9 months. This is 19.8%
of the total sample. There were 23 (2.3%) participants in methadone treatment for 6–9 months,
11 (1.1%) in Suboxone, and 13 (1.3%) in individual counseling. There were 11 (1.1%) in group
counseling, 0 in IOP, and 3 (.3%) in Vivitrol. There were 19 (1.9%) in Suboxone and counseling
simultaneously, and 9 (.9%) in psychiatry, counseling, and Suboxone simultaneously. There
were 23 (2.3%) in methadone and counseling simultaneously. Of the total population, there were
28 (2.8%) in psychiatry, counseling, and methadone simultaneously, 15 (1.5%) in individual and
group counseling simultaneously, and 11 (1.1%) in psychiatry, counseling, and Vivitrol
simultaneously. There were 2 (.2%) in Vivitrol and counseling simultaneously, and 29 (2.9%) in
psychiatry and counseling simultaneously.
Of the total sample, 153 (15.3%) participants remained in treatment for 9–12 months.
There were 19 (1.9%) participants in methadone treatment for 3–6 months, 7 (.7%) in Suboxone,
10 in individual counseling, 6 (.6%) in group counseling, 0 in IOP, 3(.3%) in Vivitrol, 14 (1.4%)
in Suboxone and counseling simultaneously, and 13 (1.3%) utilized psychiatry, counseling, and
methadone simultaneously. Of the total sample 26 (2.6%) utilized methadone and counseling
simultaneously. Of the total population 13 (1.3%) utilized psychiatry, counseling, and methadone
simultaneously, 19 (1.9%) utilized individual and group counseling simultaneously, and 6 (.6%)
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utilized psychiatry, counseling, and Vivitrol simultaneously. Out of the entire sample, 4 (.4%)
utilized Vivitrol and counseling simultaneously, and 19 (1.9%) utilized psychiatry and
counseling simultaneously.
Of the total sample, 192 participants stayed in treatment for 12 or more months. This is
19.2% of the total sample. Of the 192 participants 33 (3.3%) participants utilized methadone
treatment, 10 (1%) participants utilized Suboxone treatment, 6 (.6%) participants utilized
individual counseling, 4 (.4%) participants utilized group counseling, 26 (2.6%) participants
utilized IOP treatment, and 6 (.6%) participants utilized Vivitrol treatment. Of the 192
participants, 22 (2.2%) utilized Suboxone and counseling, 17 (1.7%) utilized psychiatry,
counseling, and Suboxone simultaneously, 29 (2.9%) utilized methadone and counseling
simultaneously. Of the total population 31 (3.1%) utilized psychiatry, counseling, and methadone
simultaneously, 10 (1%) utilized individual and group counseling simultaneously, and 6 (.6%)
utilized psychiatry, counseling, and Vivitrol simultaneously. Out of the entire sample, 4 (.4%)
utilized Vivitrol and counseling simultaneously, and 38 (3.8%) utilized psychiatry and
counseling simultaneously.
Conclusion
The treatment modalities that had the most patients who were successfully included
methadone, methadone with counseling, and methadone with psychiatry and counseling. There
were far more men who were successful than women with a 66.7 % success rate. Caucasian
ethnicity had the most successful clients with 75.9 %. Seventy-five percent of successful clients
were unemployed. Eighty-one percent of the successful population were not homeless. These
percentages appear to insinuate that an unemployed male who is not homeless, who utilized
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methadone treatment alone or in conjunction with another treatment, would have the highest
chance of being successful.
Results
Statistical Test and Assumptions
CTA can give an easy to understand the depiction of relationships between groups that
can assist in predicting events (Aksu, & Reyhanlioglu Keceoglu,2019). The results analyzed in
the category tree were taken from the successful portion of the population since the factors of
successful treatments are what is examined. The categories that were considered successful
treatments are 6–9 months, 9–12 months, and more than 12 months. These three categories
together contain 543 participants, meaning 54.3% of the participants in the study are considered
to be successful.
For the supporting research questions and hypothesis, the assumptions of normality tests
were different from the overall CTA assumptions. This writer used a one-sample t test to analyze
the means of the average (expected) success rate as compared to the actual success rate for each
question to determine whether the difference is statistically significant. In order to use an
independent samples t test, each subject must fit into only one category, and the dependent
variable must be normally distributed. This writer used a simple histogram to observe that there
was a normally distributed bell curve for each sample. This helped to illustrate that the data is
normal and meets the assumption (Leander & Norgren, 2019).
The CTA analyzed the factors contributing to successful treatment episodes, which
included those clients in treatment for 6–9 months, 9–12 months, and 12 months or more. The
CTA separates the root node into branches based on the most strongly predictive factors. For
instance, if the gender factor was demonstrated to be a factor predictive of treatment success, the
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tree would split into female and male category branches, with the male records assigned to the
male category branch and the female records assigned to the female category branch. The most
influential factors create branch splits higher in the tree, and the less influential factors create
branch splits lower in the tree.
After the branches have been split according to the factors that are most predictive of
treatment success, each record is designated to a node. A node, for instance, could contain all
records of males who were employed and treated with IOP. The analysis for this study utilized a
node minimum of 5, meaning that the branches could no longer split if this required a resulting
node to contain fewer than five records.
The significance level for the decision tree was set at α=.1. This was done because when
the significance level was set at α=.05 only a few factors were deemed significant, meaning there
were too few categories to have a valid study. When this writer changed the significance level to
α=.1, the CTA generated better results and multiple variables were considered significant. This
gave this writer more predictors of success. The classification tree can also be set to merge
categories (combine multiple variables into one category) in its branches or to not merge them
depending on the significance level set for merging categories. For example, if there was not a
big difference between the significance of methadone and Suboxone the study would combine
these two categories into one node. This CTA was created with a .5 significance level for
merging categories to prevent the categories from merging together. This allowed this writer to
analyze each category more thoroughly. Although this did prevent many of the categories from
merging, the .5 significance level was still not enough to prevent every category from merging.
The categories that merged were psychiatry, counseling and methadone merged with IOP;
psychiatry, counseling, and Vivitrol and group counseling merged with group counseling.
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The overarching research question was: Under what conditions are opioid use disorder
treatment successful? The assumption tests used for a CTA include random sampling, a single
category assignment of subjects, and the algorithm being accurately placed into the correct node
(Milanović & Stamenković, 2016). This writer ensured that sampling was random from a
collection of 5,000 records by choosing 1,000 records with randomly assigned numbers assigned
to each client with the app Random Num for the iPhone. The CTA program automatically
guaranteed that each subject was placed in only one category.
Hypotheses
RQ1: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with MMT?
H01: There will not be a statistically significant difference between the average (overall sample)
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with MMT.
The success rate of those on MMT was 56.4%. When tested against the overall sample
success rate (54.3%) with a one-sample t test (confidence interval 95%), it is determined that
there is not a significant difference (t=2.899, p=.101). Therefore, the null hypothesis is not
rejected as those treated with this modality did not have a significantly higher than average rate
of treatment success.
The success rate of those treated with MMT and counseling was 63% when tested against
the overall sample success rate (54.3%) with a one-sample t test (confidence interval 95 %) it is
determined that there is a significant difference (t=3.341, p=.079). Therefore, the null hypothesis
is rejected as those treated with this modality have a significantly higher than average rate of
treatment success.
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The success rate of those treated with MMT, psychiatry, and counseling was 48.7% when
tested against the overall sample success rate (54.3%) with a one-sample t test it is determined
that there is a not significant difference (t=2.011, p=.182). Therefore, the use of MMT is
predictive of treatment success when used in conjunction with counseling.
RQ2: Is there a statistically significant difference between expected and actual success rate in
those with opioid use disorder when treated with Suboxone?
H02: There will not be a statistically significant difference between the average overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with Suboxone.
The success rate of those on Suboxone was 48.3%. When tested against the overall
sample success rate (54.3%) with a one-sample t test (confidence interval 95%) it is determined
that there is a significant difference (t=-2.993, p=.096). Therefore, the null hypothesis is rejected,
but those treated with this modality have a significantly lower than average rate of treatment
success.
The success rate of those treated with Suboxone and counseling was 52% when tested
against the overall sample success rate (54.3%) with a one-sample t test (confidence interval
95%) it is determined that there is not a significant difference (t=.744, p=.534). Therefore, the
null hypothesis is not rejected.
The success rate of those treated with Suboxone, psychiatry, and counseling was 49%
when tested against the overall sample success rate (54.3%) with a one-sample t test it is
determined that there is a significant difference (t=-6.346, p=.024). Therefore, the use of
Suboxone is not predictive of treatment success.
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RQ3: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with Vivitrol?
H03: There will not be a statistically significant difference between the average overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with Vivitrol.
The success rate of those on Vivitrol was 55.6% when tested against the overall sample
success rate (54.3%) with a one-sample t test (confidence interval 95%) it is determined that
there is a significant difference (t=-28.790, p=.001). Therefore, the null hypothesis is rejected, as
those treated with this modality have a significantly higher than average rate of treatment
success.
The success rate of those treated with Vivitrol, psychiatry, and counseling was 66% when
tested against the overall sample success rate (54.3%) with a one-sample t test (confidence
interval 95%) it is determined that there is not a significant difference (t=-2.849, p=.104).
Therefore, the null hypothesis is not rejected.
The success rate of those treated with Vivitrol and counseling was 58% when tested
against the overall sample success rate (54.3%) with a one-sample t test (confidence interval
95%) it is determined that there is a significant difference (t=-12.015, p=.007). Therefore, the use
of Vivitrol is predictive of treatment success when used alone or in conjunction with counseling,
but only in the absence of psychiatry.
RQ4: Is there a statistically significant difference between the expected and actual success rates
in those with opioid use disorder when treated with individual counseling?
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H04: There will not be a statistically significant difference between the expected overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with individual counseling.
The success rate of those in individual counseling was 41% when tested against the
overall sample success rate (54.3%) with a one-sample t test (confidence interval 95 %) it is
determined that there is not a significant difference (t=-1.609, p=.249). Therefore, the null
hypothesis is not rejected.
The success rate of those treated with individual counseling and psychiatry was 60%
when tested against the overall sample success rate (54.3%) with a one-sample t test (confidence
interval 95%) it is determined that there is not a significant difference (t=2.868, p=.103).
Therefore, the null hypothesis is not rejected.
The success rate of those treated with individual counseling and group counseling was
61% when tested against the overall sample success rate (54.3%) with a one-sample t test
(confidence interval 95%) it is determined that there is not a significant difference (t=.333,
p=.771). Therefore, the use of individual counseling alone is not predictive of treatment success.
RQ5: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with group counseling?
H05: There will not be a statistically significant difference between the expected overall sample
success rate and actual success rates in those with opioid use disorder or a co-occurring disorder
when treated with group counseling.
The success rate of those in group counseling was 53% when tested against the overall
sample success rate (54.3%) with a one-sample t test (confidence interval 95 %) it is determined
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that there is a not a significant difference (t=-2.849, p=.104). Therefore, the use of group
counseling alone is not predictive of treatment success.
RQ6: Is there a statistically significant difference between the expected and actual success rates
in those with opioid use disorder when treated with IOP?
H06: There will not be a statistically significant difference between the average sample success
rate and actual success rates in those with opioid use disorder or a co-occurring disorder when
treated with IOP.
The success rate of those in IOP was 6% when tested against the overall sample success
rate (54.3%) with a one-sample t test (confidence interval 95 %) it is determined that there is a
significant difference (t=-36.790, p=.001). Therefore, the use of IOP alone is not predictive of
treatment success.
RQ7: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with psychiatry? This question was omitted due to
the lack of data available for this category.
RQ8: Is there a statistically significant difference between expected and actual success rates in
those with opioid use disorder when treated with family intervention? This question was omitted
due to lack of data available for this category.
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psychiatry and counseling; psychiatry; counseling; and methadone merged with IOP; methadone;
Suboxone and counseling; individual counseling; Suboxone; group counseling merged with
psychiatry with counseling and Vivitrol; psychiatry with counseling and Suboxone; Vivitrol and
counseling; Vivitrol; individual counseling with group counseling; and methadone with
counseling. Nodes 15–32 were the next most influential factors under various treatment types.
As the data was analyzed it was apparent that two variables contribute a role in treatment
episodes. Therefore, employment status and housing status were added to the study. Whether the
client had OUD only, or a co-occurring disorder was not a significant factor in treatment success,
so it was omitted from the results.
Table 7
Tier 2 Influenced psychiatry with counseling and methadone or IOP
Influenced psychiatry with counseling and
Number
methadone; IOP (tier 2)
Employed or unknown
15
Unemployed
55
total
70

Percent
2.8
10.1
12.9

When a client is homeless, they have many more barriers to attending treatment, and even
more barriers to obtaining success (Klop et al., 2018). Employment could affect treatment in
ways that are conducive to treatment or the opposite. Employment is a goal for many of those
who are healing from OUD. Keeping employment could help motivate clients to remain in
treatment (Dunn et al., 2013). Employment was a predictor of success for those who were treated
with psychiatry in conjunction with counseling as well as those who were treated with
methadone merged with IOP
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Table 8
Tier 3 Influenced psychiatry with counseling and methadone or IOP and were unemployed
Influenced psychiatry with counseling and
Number
Percent
methadone; IOP and were unemployed (tier 3)
Homeless
5
0.9
Not homeless
50
9.2
total
55
10.1

For those who were unemployed, the next most influential factor in psychiatry with
counseling and methadone, as well as IOP was housing status (p=0.042). There were 50 (9.2%)
participants who were not homeless but were unemployed and had a successful treatment
episode with psychiatry in conjunction with counseling, and methadone or IOP. Five clients
(0.9%) who were homeless and unemployed had a successful treatment experience with this
same treatment modality.
Table 9
Tier 3 Influenced psychiatry with counseling and methadone; IOP and were employed or
unknown employment status
Influenced psychiatry with counseling and
Number
Percent
methadone; IOP and were employed or
unknown employment status (tier 3)
Ages 22–28, 34–40, and 40–49
9
1.7
Ages 18–21 and 29–33
6
1.1
total
15
2.8

For those who were employed, or their employment status was unknown, and chose the
treatment of either psychiatry, counseling, and methadone or IOP, the next most influential factor
in their success was age (p=0.017). Nine (1.7%) clients who were in the age ranges of 22–28,
34–40, and 40–49 had success with this treatment. Six clients (1.1%) between the ages of 18–21
or 29–33 also were successful.
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Table 10
Influenced Suboxone and counseling
Influenced Suboxone and counseling
Employed
Unemployed or unknown
total

Number
14
30
44

Percent
2.6
5.5
8.1

Employment and age were predictors of success for those who were treated Suboxone
maintenance in conjunction with counseling. This category contributed to 8.1% of the sample.
Most of the clients who utilized this treatment modality were unemployed.
Table 11
Tier 2-c Influenced Suboxone
Influenced Suboxone
Ages 19–21, 29–33, 50–59
Ages 34–40, 40–49
Ages 22–28
total

Number Percent
13
2.4
8
1.5
7
1.3
28
5.2

Age was a significant factor in successful treatment for those who were treated with
Suboxone. Clients who were 19–21, 29–33, and 50–59 had a 2.4% success rate. Clients aged 34–
40 and 40–49 had the second-highest success rate in this category with 1.5%, and ages 22–28 has
the least amount of successful clients.
Table 12.
Tier 2-d Influenced group counseling or Vivitrol with psychiatry and counseling
Influenced group counseling or Vivitrol with
Number
psychiatry and counseling
Caucasian, European, and unknown ethnicities
34
African American, Hispanic
8
total
42

Percent
6.3
1.5
7.8
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Ethnicity was a predictor of success for those who were treated with group counseling.
Those treated with Vivitrol used in collaboration with psychiatry and counseling also had
success. The ethnicity with the most success were Caucasians, Europeans, and unknown
ethnicities.
Table 13
Tier 2-e Influenced methadone and counseling
Influenced methadone and counseling
Male
Female
total

Number
54
34
88

Percent
9.9
6.3
16.2

A significant variable for the treatment modality of methadone in conjunction with
counseling was gender. The above table demonstrates that more men were successful with this
treatment, percentage wise, than females. The total number of males and females who utilized
this treatment was 88.
Table 14
Tier 3-b Influenced methadone and counseling
Influenced methadone and counseling (tier 3)
Caucasian, European, and unknown
African American, Hispanic, Asian
total

Number
40
14
54

Percent
7.4
2.6
10

The next most influential variable for success in methadone and counseling together for
males was ethnicity. The most successful ethnicities were Caucasians and Europeans. The
second most successful group was African Americans, Hispanics, and Asians.
Summary
This study was created to determine under what conditions are opioid use disorder
treatment most effective. After analyzing data collected on one-thousand patients, some
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treatments proved to be more effective than others. A treatment modality that was shown to be
significantly more successful than the overall success rate was vivitrol, which was an unexpected
outcome. Some factors were significant in influencing the success of these treatments. There
were a few treatment modalities that did not have any significant factors influencing their
success. These modalities include psychiatry in conjunction with counseling; methadone;
psychiatry along with counseling and Suboxone; Vivitrol; Vivitrol with counseling; and
individual counseling together with group counseling. An area that was, surprisingly, not
included in the CTA due to it not being a significant variable to treatment success was mental
health. This is curious and could be an area for further study.
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CHAPTER FIVE: CONCLUSION
Overview
This study was performed to determine under what conditions OUD treatment is most
effective. A random sample of 1,000 patients from a drug treatment center in Massachusetts that
provides multiple types of treatments for those with OUD was collected and analyzed for
successful treatment episodes. A successful treatment episode was defined as six months or
longer. Variables pertaining to the patients who were deemed to have been successful were
analyzed to determine which variables could have contributed to the patient’s success. In this
chapter, the results of the study are discussed along with the literature that was provided. To
conclude the chapter the implications of the study, as well as the limitations of the study and
suggestions for future research, are given.
Discussion
This study was performed to ascertain under what conditions OUD treatment is most
effective. Some treatments produced higher than expected success rates, while some were lower
than expected.
Methadone
The first question explored was, “Is there a significant difference between actual and
expected success rates in those with opioid use disorder when treated with methadone
maintenance?” The use of MMT was predictive of treatment success only when used in
conjunction with counseling.
This appears to contradict some of the literature that was researched which promoted
methadone as a superior treatment to most other treatments. Studies were done by Higgins &
company and Paulus & Halliday suggested that methadone was a very effective replacement
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therapy and clients were able to abstain from illicit opioids at a high rate (Mattick et al., 2014).
The study even gave half of the patients a reduced dose and half a consistently higher dose of
methadone and reported that the patients with the reduced dose had illicit drugs in their system,
while the others did not. While methadone used alone did not have a significantly better success
rate when used in conjunction with counseling it did. This suggests that simply treating the
physical symptoms of OUD is not enough. Working on the emotional and cognitive reasons for
why one uses opioids is crucial to successful healing as Bowen states in his writings (Bowen et
al., 2017). Methadone. psychiatry, and counseling all used in conjunction not having a
significantly better success rate than other treatments could be due to the level of psychiatric
severity of these patients. It could be that methadone is not the best OUD treatment for those
with psychiatric issues.
Suboxone
Suboxone as a solo treatment was determined to have a significantly lower success rate
than average. Suboxone, when used with counseling, did not have a significant difference in
success from the average success rate. Suboxone when used with counseling and psychiatry also
had a significantly lower success rate than other treatments. This could be due to the immense
potential for abusing this medication, as well as not taking the medications properly to sell, or to
allow illicit opioid use as described in studies by Furst (2013) and McLean and Kavanaugh
(2019). If the patients are not using this medication properly, premature relapse is inevitable.
Vivitrol
Vivitrol alone was deemed to be more successful than the average success rate, as was
Vivitrol in conjunction with counseling. Also, when Vivitrol was utilized with counseling and
psychiatry there was a significant difference between these treatments and the average treatment
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success rate. Therefore, the use of Vivitrol is predictive of treatment success when used alone or
in conjunction with counseling, but only in the absence of psychiatry.
Vivitrol is a long-acting medication that is in the patient’s system for 1 month at a time,
therefore taking away the temptation to not take the medication or sell it. It will also cause the
patient extreme discomfort if the patient does use an illicit opioid. These factors could contribute
to the successful nature of this medication and were discussed in the literature review in
reference to studies by Syed and Keating (2013). These results appear to support their findings.
Although Vivitrol was deemed to be a successful treatment when used by itself and in
conjunction with other treatments, no variables were significant enough to be included as being
influential to this treatment modality.
Counseling, Group Counseling, IOP, and Psychiatry
Those treated with counseling, counseling with psychiatry, IOP, and counseling along
with group counseling were not significantly more, or less, successful than other treatments.
Considering that some of the other treatments consist of powerful narcotic medications, it is
significant that counseling was just as effective, even though it was not more effective than these
treatments. This speaks to how effective developing coping skills to manage damage from past
traumas, maladaptive thinking patterns, and dysfunctional behaviors can be for an invested
patient. Lorman (2013) concurs with this assumption and reported that those who actively
institute the content of their work done in counseling in their lives can achieve great success.
Group counseling and intensive outpatient both were not significantly more or less
successful than other treatments. Kaisler et al. (2009) stated that patients need consistent support
in their first year of recovery as their brains are still healing from the addiction. Both types of
treatment weigh heavily on peer support. Lorman (2013) discussed the importance of peer
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support in the recovery process as well. He states that those with peer support have a much better
chance of successful recovery.
Predictive Factors
This analysis has also provided some insight into factors that could influence success in
opioid use disorder treatments. The treatment modalities had a significant variance between
them. This outcome suggests that not all treatments are equal, and some appear to be more
successful than others under certain conditions. A few more factors were added to the data than
were originally planned. Employment status and housing status were added because there were
significant amounts of information on these two variables to suggest that these could be
significant variables to treatment success. Employment was an influential variable in treatments
including psychiatry with counseling and methadone, IOP, and Suboxone with counseling.
Housing status was a significant factor in successful treatment episodes including psychiatry
with counseling and methadone, IOP, and Suboxone with counseling.
One of the variables that contributed to some successful treatment episodes was ethnicity.
Ethnicity played a part in group counseling as well as psychiatry in conjunction with counseling
and Vivitrol. It also played a part in methadone maintenance along with counseling. Those who
were Caucasian or European were more likely to make it to the 6-month mark than Hispanics,
African Americans, and Asians. This could be because the geographical area is predominantly
Caucasian/European. Culture could also play a part in the difference in successful cases between
Caucasians and other ethnicities. Some cultures see asking for help as a weakness or
embarrassment (Paul et al., 2020). Some do not recognize SUDs as actual medical, diagnosable
conditions, but only as poor choices easily remedied by making good choices, depending on the
attitudes of the country of origin concerning substance use (Paul et al., 2020). Many cultures see
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alcohol abuse as much more acceptable than drug abuse (Paul et al., 2020). Some do not
understand the details of the treatment due to language barriers (Paul et al., 2020).
Another variable that was significant to some successful treatment methods was age in
that those who are of 18–21, 28–33, and 50–59 are more likely to make it to the 6-month mark
than the other age brackets. Curiously, this skips an age bracket between each age category.
Some reasons that these age brackets were more successful could be that those in the 18–21
range most likely have not been using for too long, so this could be their first, or one of their
first, treatment attempts (Mohammad, Busse, Shub, & Sarkar, 2016). Suboxone is the less potent
of the MAT choices, and it does not require as intense a commitment as the client is not required
to present to treatment every day like they are with methadone maintenance (Mattick et al.,
2014). Those who are 50–59 have usually been battling their addiction for years. Clients who
make it to this age in active substance use are battered and tired. They will, many times, seek a
low maintenance treatment that can still help them while not imposing too greatly on their lives
maintenance (Mattick et al., 2014). Those who are 28–33 are usually getting married, settling on
careers, feeling like they need to get their life in order. They may have young children and need
treatment where they can still work or function as normally as possible in whatever capacity
(Mohammad et al., 2016).
Employment was also a significant factor in successful treatments in that those who were
unemployed were more likely to make it to the 6-month mark. This could be due to those who
are unemployed having more time to engage in their treatment (Dunn et al., 2013). Unemployed
patients may also have more treatment access because they have state insurance that covers more
than insurance they might have, or lack thereof, if they were working (Dunn et al., 2013).
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Those who were employed also had some treatment success, primarily with Suboxone
maintenance (Dunn et al., 2013). Clients can take Suboxone just like any other prescription.
They do not need to come into treatment daily. Also, it is more difficult to use illicit opioids
while on Suboxone because of naloxone which causes illness if used with street opiates (Tanner
et al., 2011). Consequently, someone who is employed may be able to do this with minimal
discomfort and life disruption.
Gender was a significant variable for those who had success in methadone in conjunction
with counseling. Fifty-four (8.3 %) males were successful as opposed to 34 (9.7%) females.
Females have been shown to use substances to cope with negative feelings most of the time
while men use more for the pleasure it gives them (Cornish et al., 2010). Because of this females
might be able to remain sober for longer periods of time if they are in treatment because they are
addressing the reasons that they began using opiates in the first place. Although percentage-wise
females were more successful than males, it is interesting to note the large gap in how many men
presented for treatment as opposed to females. In the overall sample, there were 647 males
included and 349 females. It is a possibility that a large reason for so many more men seeking
treatment is because women are more likely to have responsibilities with caring for children or
other family members. This can contribute to either not being able to come for treatment or for
fear of losing custody of their children. Although SUD treatment is here to help, professionals
have still mandated reporters. If a mother presents for treatment and discloses that she has been
using illicit substances daily, and is the primary caregiver of young children, there is a strong
possibility that she would be reported to the department of children and families. This could
result in the children being removed from the home (Suchman, 2016). Another reason that
women might not seek treatment as often as men is stigma. If the woman is a mother they might
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fear judgment by treatment professionals, or might be unable to cope with the judgment they
place upon themselves (Gartner et al., 2018).
Homelessness also presented itself as a significant factor in treatment success in that
those who are homeless are less likely to make it to the 6-month mark. When a client is
homeless, they have less access to things that are essential to normal everyday living. These
things could be showers, clean clothing, and access to transportation, food, and proper rest. It is
not surprising that so many more people have had success with treatments who are not homeless
and do not have to contend with all of these barriers (Klop et al., 2018). Clients who are
homeless also normally have less access to healthy supports (Klop et al., 2018). If a person is
homeless it is usually as a last resort, meaning they no longer have support from their loved ones
Implications
Implications of the study are tremendously important. When treating families and
communities, substance abuse is a topic that will inevitably be an issue. Addiction has become a
prominent problem in America. Many families and marriages have been damaged or destroyed
by addiction. Finding out how to help the treatment to be the most successful that it can be and
studying which treatments might be the best suited to the individual can not only save lives, but
it can save families.
A Christian worldview comes into play in different ways in this study. The Bible tells us
to only depend on God. When a person is dependent on anything other than God the
consequences can be disastrous. The Great Healer is the ultimate way to health, recovery, and
contented, productive living. He gives treatment providers the tools necessary to assist those with
addiction to become well enough to be able to seek Him and depend on Him for continued
abstinence and thriving in their lives, communities, and families. When a Christian treatment
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provider is treating a patient who might not be Christian themselves, or might not even believe in
God, a Christian worldview can still be implemented into the treatment given. Because God is
the Great Healer, all effective treatments come from Him. Although the patient might not
wittingly rely on God themselves for their healing, Christian treatment providers can still give
them divine tools for them to use in their lives and in their recovery.
Limitations
This study had some limitations due to uncontrollable factors. One of those limitations
was that this writer did not have access to data concerning client’s natural supports, which is
known to be an influential factor in client success (Klostermann & O'Farrell, 2013). Clients may
feel more of a responsibility to remain clean and sober knowing that they are not only affecting
themselves but their loved ones as well. They also have someone to lean on when they are
feeling weak or having cravings to go back to their old lifestyle. Natural supports also have
greater influence when it comes to guiding the person in early recovery toward healthy
environments and behaviors (Lorman, 2013).
Another limitation of this study was that this writer had to deviate from the original plan
of defining successful treatment as 1 year. This writer changed the definition of successful
treatment to six months. This was due to not enough clients making it in treatment to this point
for the study to be viable. There have been some studies done that indicate that six months is an
acceptable definition of a successful treatment episode (Grall-Bronner et al., 2019). A shorter
time frame could have affected the results in that patient’s brains are not yet healed from an
opioid addiction after 6 months. It would be more indicative of long-term success to be able to
study patients who have remained in treatment until their brain functioning has returned to
normal.

100
A third limitation of the study was that the data was from one specific region and
therefore could only provide specific information pertaining to this area. Different regions of the
country have different severities of different types of substances, though opioids are everywhere.
Treatment options and availability vary from area to area, and lack of availability to treatment
could significantly affect treatment success in other areas.
Recommendations for Future Research
This study addressed OUD treatments and conditions affecting these treatments. In doing
this some unexplored questions came about that would benefit from further research. One of
these topics is how important are natural supports to those seeking sobriety from illicit and mindaltering substances. This could be studied in conjunction with determining how those with
addiction affect the family unit, and how they affect their communities. Families are often
destroyed by this issue (Klop et al., 2018). Those with addiction act in ways that they never
would normally, causing pain and often feeling of betrayal and helplessness. Substance use has
had a profound impact on many communities and neighborhoods. It would be interesting to
delve deeper into specific consequences on the people around the person with addiction.
Another topic that piqued the interest of this writer while studying the results was how
motherhood affects SUD treatment. Some possible issues for mothers who are seeking treatment
were brought up, but this topic could greatly benefit many who are mothers or have loved ones
who are mothers, who suffer from a substance use disorder. A study about this could reduce
stigma and bring awareness to an often-neglected demographic of women who are struggling and
are desperate for help. This type of study could also help to develop strategies for how to combat
some of the issues that might prevent them from getting help.
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Another recommendation for further study is how the same factors influence similar
treatments in other regions of the country. Further research on these factors could greatly
influence how treatment is conducted, as well as influencing understanding of the importance of
a holistic approach to treatment for opioid use disorder. A study such as this could also help
communities to access necessary funding to assist in successful treatment.
Summary
The purpose of this study was to ascertain under what conditions are OUD treatment
most effective. This study provided important data to help treatment providers to understand
what could contribute to successful opioid use disorder treatment in the future. This is important
for the obvious reason for saving lives, but it is also important because addiction affects,
families, communities, public safety, public health care, and more. Knowing which factors
influence which treatments, and which treatment are consistently effective, is extremely useful
information. For example, if it is determined that homelessness is a barrier to successful
treatment, an agency might hire someone to assist clients in obtaining a bed at a shelter while
they participate in treatment. This is just an example of why this is an important topic of study.
Treatment was considered to be successful if the client stayed in treatment for 6 months
or more. The treatments that predicted a higher than average treatment success are considered to
be successful treatments based on being in treatment for 6 months or longer include psychiatry,
Vivitrol, and counseling, methadone, and counseling, individual and group counseling,
psychiatry and counseling, Vivitrol and counseling, psychiatry methadone and counseling, and
methadone.
The other factors that were the most influential to successful treatment were ethnicity,
age, housing status, employment status, and gender. Different factors appear to influence various
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treatment modalities distinctively. There are many different possible reasons why these factors
influence treatments differently. Some of the most important implications of the study appear to
gravitate toward how the patient’s lifestyle and culture affect their success in abstaining from
opioids. This could be telling that basic needs are important to success in other areas. Perhaps
client’s human needs should be addressed in conjunction with their treatment to help them have a
chance of getting clean and sober. This could include things such as housing support, family
support, and cultural considerations.
Although some of the treatments studied were less successful than anticipated, none were
shown to not be successful at all. Every single treatment that was studied had some success. This
shows that there is value in every effort that is being put forth by treatment providers to this very
involved and complicated type of illness. Using the information gathered by this study could
hopefully encourage those who are working in this field and motivate neglected areas to be
addressed. Although this study has provided many answers it has also produced more questions
and avenues for others to continue to research.
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